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C3a and C5a anaphylatoxins are proinflammatory polypeptides released during 
complement activation. They exert their biological functions by interacting with 
the G protein-coupled receptors, C3aR and C5aR respectively. Activation of the 
complement system has been implicated in the pathogenesis of many 
inflammatory diseases including asthma. Little is known, however, about the 
expression and location of complement components in asthmatic airways. 
 
Experiments described in this thesis demonstrate the expression and 
localisation of certain complement components and their two receptors in the 
bronchial mucosa. C3a and C5a-stimulated production of remodelling mediators 
and the biological function of the anaphylatoxins on the structural cells was also 
assessed.   
 
Immunohistochemical analysis revealed elevated expression/deposition of C3 
and C5 components in the epithelium, airway smooth muscle and submucosa of 
asthmatics compared with controls, and also demonstrated expression of the 
two complement receptors on airways structural cells, including airway epithelial 
cells, endothelial cells, fibroblasts and smooth muscle cells (SMC). 
 
In general C3a was the more effective of the two anaphylatoxins in inducing 
structural cellular proliferation: C3a increased fibroblast and endothelial cell 
proliferation at a range of concentrations embracing the physiological, although 
it increased SMC proliferation only at the highest concentration (10-7 M) 




M) employed. C5a induced fibroblast proliferation but had no effect in this regard 
on the other structural cells. 
 
The anaphylatoxins induced expression of various fibroblast growth factors 
(FGFs) and their receptors by the structural cells at the mRNA level:  FGF2 was 
induced in all four cell types; FGFR1 and FGFRL1 were induced in all except 
SMC cells; FGFR4 was induced in SMC and endothelial cells; FGF11 was 
induced in fibroblast cells and FGF17 in SMC. 
 
The structural cell types were observed to release FGF2 protein spontaneously. 
In contrast to their effects on early mRNA synthesis, however, the 
anaphylatoxins effected a net inhibition of FGF2 protein release by cultured 
epithelial cells, SMC and endothelial cells. With fibroblasts, C3a increased while 
C5a decreased FGF2 production. 
 
The possible effects of C3a and C5a on the expression and release of IL-6 and 
IL-8 by airways structural cells was examined. IL-6 was released spontaneously 
only by airway fibroblasts and this release was unaffected by both 
anaphylatoxins. IL-8 was induced by C3a in fibroblasts and by C5a in 
endothelial cells. 
 
The data support the hypothesis that complement components participate in 
acute or chronic asthmatic inflammatory processes, resulting in airway structural 
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1.1 Pathogenesis of Asthma 
Asthma is a complex airway inflammatory disease characterised by chronic 
inflammation, bronchoconstriction, airway hyperresponsiveness (AHR) and 
remodelling (Ali & Panettieri 2005). 
 
It is one of the most common disorders encountered in clinical medicine in both 
adults and children (Renauld 2001). Many developed countries are in the midst 
of an epidemic of childhood asthma. According to the US 2002 National Health 
Interview Survey data, more than 8.9 million children younger than the age of 18 
have had a diagnosis of asthma (Freidin & Timmermans 2008) and reported 
incidence is increasing dramatically in many developed nations (Renauld 2001).  
 
There is a range of asthma severity, which tends to be maintained throughout 
life but may change for better or worse with age. Most patients with asthma are 
atopic (extrinsic asthma), but 10-20% are non-atopic (intrinsic asthma), and 
these patients often have a more severe form of the disease. Approximately 5% 
of patients have severe asthma that is difficult to control with maximal inhaler 
therapy and for whom new therapeutic approaches are needed (Barnes 2008). 
 
As with all chronic inflammatory diseases, asthma is thought to arise from 
interaction between genetic background and the environment, involving 
allergens, viruses, bacteria and environmental and occupational pollution (Bai & 
Knight 2005). These factors contribute to inflammation, which results in both 
airway structural change and functional muscle change, leading to excessive 





Despite asthma being multifactorial in origin, atopy, the genetic predisposition 
for the development of an immunoglobulin (Ig)E-mediated response to common 
aero-allergens, is the strongest identifiable predisposing factor for the 
development of asthma (Wills-Karp 1999). Although asthma is often 
accompanied by increased concentrations of circulating IgE, it has been difficult 
to demonstrate a precise role for IgE in the pathogenesis of asthma using 
murine models (Mehlhop et al. 1997). Nevertheless the benefits of anti-IgE 
strategies such as omalizumab argue empirically for a functional role for IgE at 
least in asthmatics who are atopic. 
 
Airway obstruction in asthma is variable and reversible (Barnes 2008). There are 
structural changes in the airways of asthmatics, which include angiogenesis, 
epithelial fragility, enlarged submucosal mucus glands, goblet cell hyperplasia, 
increased matrix deposition in the airway wall, increased airway smooth muscle 
mass, wall thickening and abnormalities in elastin (Bai & Knight 2005). A point to 
note is that all components of the airway wall have been reported to be 
thickened in asthma (Renauld 2001). Contraction of the airway smooth muscle 
(ASM) is the principal component underlying the bronchoconstriction that 
characterises the acute phase of an asthmatic attack (Renauld 2001), but 
thickening of the airway wall will exaggerate the resulting airways obstruction. 
 
It is thought that the observed structural alterations are generated as a 
consequence of chronic inflammation and contribute to the symptoms and 
physiological dysregulation seen in asthma (Renauld 2001). However, although 
symptoms may be well controlled, aspects of asthma pathology such as airway 





1.1.1 Chronic Inflammation 
Chronic inflammation of the airways appears invariably to accompany the 
clinical syndrome of asthma. Inflammation seen in asthma is mainly located in 
the larger conducting airways, and although small airways can be affected in 
more severe forms of the disease, the lung parenchyma is not affected  (Barnes 
2008). 
 
Asthmatic lungs typically show hyperinflation, mucus plugging in the airways, 
clusters of sloughed epithelial cells, and crystalline precipitates of eosinophil 
derived proteins (Renauld 2001). 
 
In asthma there is chronic inflammation of the respiratory tract, which is 
mediated by the increased expression of multiple inflammatory proteins, 
including cytokines, chemokines, adhesion molecules, inflammatory enzymes 
and receptors. In acute episodes or exacerbations the intensity of this 
inflammation increases (Barnes 2008). Persistent inflammation in bronchial 
tissues, along with the ensuing activation of epithelial, subepithelial, and smooth 
muscle cells, presumably results in the structural changes known as airway 
remodelling (Pepe et al. 2005). Chronic uncontrolled airways inflammation and 
airway remodelling remain the suggested mechanisms by which severe 
persistent asthma develops (Pepe et al. 2005). 
 
1.1.2 Airway Remodelling 
The term remodelling describes the structural changes seen in the airways of 
patients with respiratory disease. The structural changes in the airway include 
angiogenesis (Busse et al. 1999), deposition of fibrous and other extracellular 




myofibroblast differentiation and proliferation, goblet cell hyperplasia and 
neovascularisation, subepithelial fibrosis, smooth muscle hypertrophy 
(Okayama, Ra, & Saito 2007) (Figure 1.1).  Ongoing inflammation, airway injury, 
and healing are also part of the remodelling process in asthma (Cohen et al. 
2007). The changes of remodelling also include thickening of the reticular sub-
basement membrane (rbm), a significant feature of established asthmatic 
remodelling, increased numbers of submucosal glands and increased airway 
wall collagen (Bush 2008). Thickening of the epithelial rbm has been reported in 
both adults and school-aged children. However, it is not known at what age rbm 
thickening begins (Saglani et al. 2006). Nevertheless the extent of airway 
remodelling correlates with severity of asthma, at least in cross-sectional 
studies. 
 
Airway remodelling is often considered to contribute to the element of 
irreversible airflow obstruction, which is a feature of some patients with asthma 
(Saglani et al. 2006). It has been suggested that reversibility in asthma is 
associated with mild disease but with disease progression, varying degrees of 
remodelling of the airways might lead to irreversibility (Pepe et al. 2005). 
 
Overall, it can be seen that airway remodelling indicates changes in the 
composition, quantity as well as organisation of both the cellular and molecular 
components of the airway wall; alterations considered secondary to chronic 
injury and repair of the airway epithelial-mesenchymal trophic (EMT) unit (Evans 
et al. 1999). Nevertheless much of the literature on airway remodelling is 
speculative in the sense that any observed histological change are not proven to 
correlate with changes in physiology and do not correlate with clinical phenotype 





Many mediators derived from various inflammatory cells (including mast cells, 
eosinophils, neutrophils and others) are implicated in the pathogenesis of airway 
remodelling, and consequently in the process of asthma. These mediators could 
be working in an autocrine or paracrine fashion. Although the mode of 
mechanism or signalling has not been investigated here, it is believed that the 
various mediators and components could be linked and work to either 
upregulate or downregulate/suppress one another or aid in recruiting infiltrating 
cells, which results in the features of airway remodelling.  For instance, human 
mast cell mediators that modulate airway remodelling include tryptase, which 
has an effect on proliferation of fibroblasts; chymase, which degrades basement 
membrane components; and transforming growth factor beta (TGF-β) which 
affects proliferation of ASM cells (Okayama, Ra, & Saito 2007). 
 
A number of studies have demonstrated a variety of structural changes in 
asthma that are likely not reversible, including subepithelial fibrosis, smooth 
muscle hypertrophy, goblet cell and blood vessel hyperplasia, which led to the 
use of the term ‘remodelling.’ Cohen et al have shown that in subjects with 
chronic asthma, there is a progressive decline in lung function that is greater 
than in normal subjects (Cohen et al. 2007).  
 
As seen by most conducted studies and investigations, bronchoscopy and 
bronchial biopsy are the most commonly used techniques for determining the 
extent of airway remodelling (Lazaar & Panettieri 2003). However, there are still 
areas involving asthma and remodelling that are unclear, therefore 
understanding the pathogenesis and mechanisms driving airway remodelling 
could lead to new approaches to therapy and, specifically, retard the progressive 






Inflammation and remodelling commonly co-exist but their natural histories are 
uncertain. It is uncertain how changes termed “remodelling” impact on lung 
physiology, although thickening of the mucosal layer and increased smooth 
muscle contractility could in theory contribute to symptoms of asthma. It is not 
certain whether remodelling changes are cumulative or sometimes reversible, 
although it could be hypothesised that there are structural changes such as 
fibrosis and ASM which are likely not reversible. 
 
Airway inflammation precedes airway remodelling in animal models of asthma 
(Southam et al. 2007). Nonetheless, both clinical and animal studies indicate 
that the relationship between inflammation and remodelling is complex, and still 
incompletely understood (Dekkers et al. 2009). The presence of airway 
inflammation in patients with asthma is no guarantee at all for the occurrence of 
airway remodelling, and there is no clear correlation between the degree of 









1.2 Complement System 
In the late 19th century Jules Bordet discovered “complementing” antibodies in 
the plasma that recognised and eliminated pathogens. He described a heat-
labile activity in serum that could complement the ability of a specific antibody to 
cause lysis of bacteria. Today this heat-labile activity is known to comprise 
dozens of serum proteins and is known as the complement system. The 
complement system contributes to the defence against pathogens (e.g bacteria, 
virus-infected cells and parasites) through release of anaphylatoxins, 
opsonisation and lysis of pathogens, stimulation of leukocyte chemotaxis and 
activation of leucocytes releasing inflammatory molecules. 
 
Complement is known to function both in the defence against microbes and in 
the clean-up of tissues, e.g. in the disposal of immune complexes and apoptotic 
cells. To exert its biological activities, the complement system needs to be 
activated, after which it generates a variety of functional molecules. The 
complement system is composed of more than thirty plasma proteins, 
glycoproteins as well as soluble or membrane bound receptors (Guo & Ward 
2005). A number of complement proteins are proteolytic enzymes that also in 
themselves become activated by proteolytic cleavage. This protein system acts 
as an enzymatic cascade via various protein-protein interactions. The pattern of 
sequential activation produces an expanding cascade of activity, which means 
that the activation of a single molecule will lead to thousands of molecules being 
generated in the following steps. Thus, many regulatory mechanisms are 
needed to prevent uncontrolled complement activation and tissue damage.  
 
There are three recognised pathways of complement activation, those being the 




ways (Figure 1.2). Each pathway utilizes different proteins to recognize the 
activators and to initiate the cascade. However, all three pathways converge at 
the level of C3 and share a common terminal pathway. In general, the 
components of the classical pathway and the terminal pathway are designated 
with the letter C followed by a number such as C4, whereas the components of 
the alternative pathway are called “factors” and are identified with a single letter 
such as factor D. The split products of the components that are generated by 
proteolytic cleavage are distinguished from their precursors by suffix letters such 
as C4b. The classical pathway is activated by antigen-antibody complexes. The 
alternative pathway is constitutively active and directly initiated by surface 
molecules containing carbohydrates and lipids (Guo & Ward 2005). The lectin-
binding pathway is triggered by the binding of either mannose-binding lectin 
protein (MBL) or ficolin to bacterial/fungal carbohydrate structures, resulting in 
activation of MBL-associated serine proteases (MASPS), with subsequent 
engagement of complement proteins, such as C2 and C4 (Guo & Ward 2005). 
 
Traditionally, asthma was considered a simple type I hypersensitivity reaction. 
Although the complement system forms the central core of innate immunity and 
has long been appreciated for its proinflammatory properties, it had not been 
considered to contribute to the pathogenesis of allergic asthma (Baelder et al. 
2005). However, accumulated data from animal models of allergic asthma and 
from human asthmatics have fuelled new interest in the role of complement in 
the allergic response (Baelder et al. 2005).  
 
Complement activation has been implicated in the pathogenesis of many 
inflammatory and immunological diseases. As for asthma, many data suggest a 
critical role for the anaphylatoxins C3a and C5a, cleavage products of C3 and 





Complement may participate in susceptibility to asthma because of an intrinsic 
abnormality in complement activation and generation of C3a, C5a, or other 
products that affect cellular responses, resulting in Th2 predominance and 




Figure 1.2 The complement system. Activation occurs via three different pathways: 
classical, lectin and alternative pathways. In addition other proteases are able to cleave 
complement components to generate anaphylatoxins. Figure adapted from (Sarma, 






1.2.1 The third complement protein (C3)  
The most abundant complement protein in the plasma is C3, the third protein of 
the complement system, which is produced and secreted mainly by hepatocytes 
but is also synthesized outside the liver. C3 has a basal plasma concentration of 
1 mg/ml in humans which increases during inflammation (Kushner et al. 1972). It 
is composed of an alpha and a beta chain. The alpha and beta chains are 
attached to each other through a disulphide bond (Fong et al. 1990). C3 is 
cleaved upon complement activation with generation of C3a and C3b. Activation 
of the complement system causes the formation of the enzymatic complex C3-
convertase. The C3-convertase cleaves the C3 alpha chain and generates C3a; 
a small soluble anaphylatoxic fragment that stimulates leukocyte recruitment 
and activation to release pro-inflammatory cytokines (Hugli 1990). The larger 
fragment of the C3 molecule, C3b contains a thiolester bond which when 
exposed binds to target structures in the surrounding area and triggers the 
terminal part of the complement cascade (Sim et al. 1981). 
 
1.2.2 The fifth complement protein (C5)  
C5 is a similar protein to C3, being a D-globulin with a molecular weight of 
190,000 daltons, and consisting of two polypeptide chains linked by sulphide 
bridges and non-covalent bonds. C5a is a 12,000 molecular weight peptide 
derived from the chain of C5, and has anaphylatoxic and chemotactic properties 
(Monk et al. 2007). C5a has been purified and sequenced. Human C5a is 
composed of 74 amino acids which account for a molecular weight of 8,200 and 
a single complex oligosaccharide unit attached to the asparagine residue at 
position 64 accounts for the remainder of the molecular weight (Monk et al. 




biological activity but very likely regulates C5a activity in vivo. Numerous 
similarities between the primary structure of C5a and C3a point to their common 
genetic ancestry. The anaphylatoxic activity is completely, and the chemotactic 
activity partly lost following removal of the C-terminal arginine residue by the 
plasma enzyme carboxypeptidase B (also known as anaphylatoxin inactivator) 
(Monk et al. 2007). 
 
Although C3a and C5a share many similar functions, they seem to have to some 
extent opposing effects on the regulation of adaptive immunity. Thus, C5a is 
chemoattractant for T lymphocytes (Tsuji et al. 2000),  potentiates T cell 
proliferation, and drives the type 1 helper T cell (Th1)-type immune response 
(Morgan et al. 1983). In contrast, C3a has been shown to mediate 
immunosuppressive effects (Morgan et al. 1983) and also to drive the Th2-type 
immune response (Hawlisch et al. 2004). 
 
1.2.3 Complement Receptors 
Studies suggest the involvement of C3a and C5a and their cell surface G 
protein-coupled (Thangam et al. 2005) receptors C3aR and C5aR in the 
pathogenesis of asthma (Fregonese et al. 2005). Anaphylatoxins act on their 
target cells by binding to and activating highly ligand-specific membrane 
receptors (C3aR and C5aR) belonging to the family of the seven 
transmembrane domain G-protein-coupled receptors. The expression of these 
receptors is greatly increased during inflammation. C5aR is expressed on both 
myeloid cells and nonmyeloid cells including endothelial cells. Each receptor is 






Fregonese et al found the receptors to be expressed in the endothelium and 
smooth muscle cells in the lungs (Fregonese et al. 2005), whilst Thangam et al 
observed that while C3aR and C5aR were expressed in human mast cells, they 
were not present in cultured primary human or murine ASM cells. Furthermore, 
C3aR could not be detected in smooth muscle-positive cells of human trachea 
or bronchus (Thangam et al. 2005). 
 
Traditionally, C3aR and C5aR were thought to be present only on myeloid cells 
such as macrophages, neutrophils and mast cells. However, some studies have 
also demonstrated these receptors on nonmyeloid tissue cells (Drouin et al. 
2001b). C3aR and C5aR expression could be detected in alveolar epithelial 
cells, bronchial epithelial and smooth muscle cells, vascular smooth muscle, and 
endothelial cells in humans and mice (Tschernig et al. 2007). Therefore the 
receptors are present on many cell types associated with asthma. 
 
C3a and C5a may regulate AHR in asthma via the activation of their receptors in 
ASM cells (Thangam et al. 2005). The rising paradigm exhibits that C3a 
production at the airway surface serves as a common pathway for the induction 
of AHR to a range of asthma triggers such as allergens, viral infections, 
particulate matter, ozone, smoke. On the other hand C5a plays a dual 
immunoregulatory role by protecting against Th2-mediated immune responses 
during initiation of responses, and a proinflammatory role after immune 
responses are established (Wills-Karp & Koehl 2005). 
 
1.2.4 Anaphylatoxins & Asthma 
Anaphylatoxins can be defined as the pro-inflammatory complement activation 




individuals. The proteolytic cleavage of C4 results in the generation of C4a, 
which has been shown to possess only weak activity. The anaphylatoxins C3a 
and C5a are classically seen as proinflammatory mediators of allergic asthma 
that recruit inflammatory cells, induce oedema, and also cause 
bronchoconstriction (Lambrecht 2006).  
 
The anaphylatoxins C3a and C5a are released as by-products or split products 
of complement activation and modulate innate immunity. Besides the two pro-
inflammatory anaphylatoxins, the membrane attack complex (MAC) is also 
generated. These activation products appear to be responsible for promoting 
and perpetuating inflammatory reactions despite not being the initiating factors 
in the inflammatory disorders (Guo & Ward 2005).  C3a and C5a are responsible 
for recruiting and activating leukocytes, particularly phagocytic cells such as 
granulocytes and monocytes and macrophages (Tschernig et al. 2007). These 
anaphylatoxins perform their function by engaging specific receptors on target 
cells.  
 
C3a mediates an inflammatory response through cell activation to induce, for 
example, chemotaxis and histamine release. C3a may influence the 
inflammatory response through its effects on cellular activation and chemotaxis. 
It is a chemotactic molecule for eosinophils and mast cells and stimulates 
release of histamine from mast cells as well as basophils (Drouin et al. 2002) 
(Table 1.1). 
 
The C5 protein is cleaved downstream of C3 into C5a and C5b, which forms the 
first part of the complement MAC. The C5 gene was identified as a susceptibility 
locus for human allergen-induced asthma (Karp et al. 2000). Certain C5 alleles 




adult and childhood asthma. C5aR targeting in an established allergic 
environment reduces airway inflammation and AHR, suggesting a beneficial 
effect of C5aR blockade in asthma (K+Âhl et al. 2006). The contribution of C5 to 
other major biological hallmarks of asthma (besides enhanced AHR in mice) has 
not been evaluated (Drouin et al. 2006). 
 
Like C3a, C5a mediates an inflammatory response through cell activation to 
induce chemotaxis and histamine release. C5a also regulates T cell responses 
(Lalli et al. 2008); T cells have a crucial role in asthma and different subsets are 
involved in orchestrating inflammation (Lalli et al. 2008). 
 
Through its chemotactic and cell activation properties, C5a has been implicated 
in regulating the downstream inflammatory cascade which results in a massive 
migration of inflammatory cells into the bronchial airway lumen that triggers the 
release of multiple harmful inflammatory mediators (Peng et al. 2005). Also to 
note, like C5a, C5b-9 also induces potent biological responses, including 
anaphylatoxic responses, inflammation, tissue injury, and cell lysis at very low 
concentrations (Peng et al. 2005). The role of activated C5 components in 
sustaining an ongoing airway response to allergen challenge has previously 
been demonstrated (Peng et al. 2005). 
 
The release of C3a and C5a anaphylatoxins contributes significantly to 
inflammation. C3a and C5a are specifically released into challenged asthmatic 
lungs, and the inflammatory infiltrate of eosinophils and neutrophils correlates 
highly with the local production of anaphylatoxins (K+Âhl et al. 2006).  
 
Both anaphylatoxins are potent mediators of inflammation, but they also exert 




C3a and C5a are chemotactic for monocytes and mast cells, cause respiratory 
burst and secretion of proinflammatory cytokines from macrophages, and trigger 
mast cell degranulation (Ellati, Dahinden, & Church 1994). Furthermore, C5a 
has been shown to cause upregulation of adhesion molecules on endothelial 
cells (Albrecht et al. 2004), and both C3a and C5a have been shown to induce 
expression of proinflammatory cytokines in cultured human umbilical vein 















 Potent activator-degranulation 
 Secretes mediators: preformed-
histamine, newly synthesized 
lipid- PGs (PGD2) and LTs (C4), 
cytokines, growth factors and 
chemokines 





 Potent activator-degranulation 
 Produce mediators including 





 Potent activator 
 Produce mediators including 
platelet-activating factor 





 Potent activator 






 Stimulating effector functions 
 Activation and chemotaxis 
 Produce lipids (PAF, LTA4), 
cytokines (TNF-α TGF-β, IL-6), 
proteases (elastase, 




Table 1.1 Effects of C3a and C5a on inflammatory cells in asthma. PG, 
prostaglandin; LT, leukotriene; PAF, platelet-activating factor; cys-LT, cysteinyl 
leukotriene; TNF, tumour necrosis factor; TGF, tumour growth factor; IL-6, interleukin 6 









1.2.5 Complement in animal studies 
Animal models have been useful in testing hypotheses of asthma pathogenesis. 
Studies in murine models have suggested the involvement of C3a and C5a in 
the development of allergic asthma (Taube et al. 2003). Taube et al found the 
inhibition of complement activation decreases airway inflammation and 
hyperresponsiveness in mice (Taube et al. 2003).  
 
Reports from some laboratories including those of Drouin et al have 
documented the importance of complement activation, the C3a anaphylatoxin, 
and its receptor, C3aR, in promoting Th2 effector functions in a mouse model of 
bronchopulmonary allergy (Drouin et al. 2006). Drouin et al found that all 
features of the experimental allergic asthma model are either abrogated or 
severely reduced in the genetic absence of the C3aR (Drouin et al. 2002). 
These results suggest that ligands of C3aR may make a major contribution to 
allergic lung disease.  
 
Drouin and coworkers showed C3aR-deficient mice were protected against 
AHR, and showed decreased Th2-cell responses, including reduced IL-4 
production (Drouin et al. 2001a). Further still, in another study involving 
challenge of antigen-sensitised animals, C3 deficient mice showed diminished 
AHR, lung eosinophil infiltration and IL-4 production as well as reduced Ag-
specific IgE and IgG1 responses, clearly demonstrating that these features of 
asthma are significantly attenuated in the absence of C3 (Drouin et al. 2002). 
These data provide compelling evidence that C3a and C3aR have the 
propensity to mediate much of the pulmonary inflammation observed in the 




play a significant role in bridging innate and adaptive Th2 immune responses in 
asthma (Drouin et al. 2002). 
 
The role of C5 in asthma remains controversial. Peng et al examined the 
contribution of C5 in mice at three critical checkpoints during the course of 
disease- those being a) initiation of airway inflammation, b) maintenance of 
AHR, and c) sustainment of an ongoing airway response to allergen provocation 
(Peng et al. 2005). Their results indicate that C5 is probably activated 
intrapulmonarily after infections or exposure to allergen and that C5 inhibition 
has profound effects at all three critical checkpoints (Peng et al. 2005). 
 
Drouin et al’s data suggest that C5a plays an important protective role in allergic 
lung disease by suppressing inflammatory responses and Th2 effector functions 
observed in their experimental model. There is a suggestion that C5a may play 
a significant role in tempering inflammation in Th2-driven diseases such as 
asthma (Drouin et al. 2006). Mice lacking C5aR have a reduced ability to clear 
an infection and to mount virus-specific CD8+ T cell responses. Also, C5-
deficient animals have exacerbated Th2-cell responses in an experimental 
allergic asthma model (Hawlisch et al. 2005). 
 
1.2.6 Complement in human studies 
There are reports of exaggerated complement production in the lungs of 
asthmatics which support a causal role for altered anaphylatoxin production in 
human disease (Wust et al. 2006). 
 
Many studies have reported elevated C3a and C5a concentrations in 




et al. 2007). C3a and C5a were reported to be elevated in the BAL of individuals 
with asthma compared with healthy control subjects at baseline (Nakano et al. 
2003). Following allergen challenge, C3a is generated in the lung of subjects 
with asthma but not healthy subjects (Nakano et al. 2003;Krug et al. 2001). Krug 
and colleagues demonstrated elevated levels of both C3a and C5a in BAL 
following segmental allergen challenge of individuals with asthma, whereas no 
elevations were observed in normal individuals (Krug et al. 2001). The role of 
C5a, however, may be diverse in allergic disease since it was noted to exert 
anti-inflammatory effects as well (Tschernig et al. 2007). This evidence is largely 
circumstantial, showing that C3a and C5a are there but not what they do, hence 
making it necessary to investigate what the anaphylatoxins might do in asthma. 
 
1.3 Fibroblast Growth Factors 
Fibroblast Growth Factors (FGFs) have been discovered across many species 
from nematodes to man; they were originally isolated from the brain and pituitary 
gland (Itoh 2007). The FGF family contains at least 23 members, being one of 
the largest families of growth factors, and its members are named FGF1 to 
FGF23. These growth factors are recognised for their functions in lung 
organogenesis and involvement in homeostasis and regenerative processes in 
adult tissues (Marek et al. 2009). FGF proteins have been shown to induce 
effects on mesodermal and neuroectdermal cells and play a role in 
angiogenesis, inflammation, wound repair, cell growth, tissue patterns, embryo 
development, metabolic regulation, cell migration, tissue repair, and 
maintenance (Nugent & Iozzo 2000). FGF1-FGF23  have been identified in 
humans and mice (Itoh 2007). Most FGFs are secreted proteins with cleavable 
N-terminal signal peptides (Itoh 2007). These FGF genes are expressed 




restricted adult tissues, indicating their potential roles in development (Itoh 
2007). FGFs may well play a pivotal role in regulating airway wall remodelling. A 
number of studies have demonstrated that various FGFs contribute to chronic 
inflammatory and tissue repair processes as well as to fibrosis in chronic airway 
diseases such as asthma (Itoh 2007).  The genes for FGF1 and FGF2 are 
widely expressed in developing and adult tissues. The genes for FGF3-FGF6 
were identified as oncogenes, whilst FGF7, FGF8, and FGF9 proteins were 
isolated as growth factors for keratinocytes, an androgen-induced growth factor 
from carcinoma cells, and a glia-activating factor from glioma cells, respectively 
(Itoh 2007). FGF10 plays a role in stimulation of the migration and proliferation 
of keratinocytes (Yun et al. 2010). Smallwood et al isolated or identified FGF11-
FGF14 genes from the retina by using a combination of random complementary 
(c)DNA sequencing, homology-based searches of nucleotide sequence 
databases, and homology-based PCR (Smallwood et al. 1996). FGF1, FGF2, 
and FGF11-FGF14, however, are not secreted proteins, and also do not have N-
terminal hydrophobic sequences (Smallwood et al. 1996). Although FGF11-
FGF14 are not secreted, but function within cells (Itoh 2007), they bear strong 
sequence similarity to other FGFs. However, the biochemical and functional 
properties of FGF11-FGF14 are largely unrelated to those of other FGFs (Itoh 
2007). FGF11-FGF14 function within cells in an FGFR-independent manner 
(Itoh 2007). 
 
FGF1 and FGF2 might be released from damaged cells or by an exocytotic 
mechanism that is independent of the endoplasmic reticulum-Golgi pathway. By 
phylogenetic analysis, the human FGF gene family can be divided into seven 
subfamilies (Figure 1.3): FGF1, FGF4, FGF7, FGF8, FGF9, FGF11, and FGF19 
(Itoh 2007). Members of the same FGF subfamily have essentially similar 
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1.3.1 FGF Receptors 
Most FGF signalling is mediated by activation of FGF receptors (FGFR) proteins 
(Itoh 2007). FGFRs belong to the family of receptor tyrosine kinases (RTKs).The 
FGFs exert their function through interactions between heparin-like 
proteoglycans and receptors (Itoh 2007). They require the glycosaminoglycan 
(GAG) side chains of heparan sulphate proteoglycans (HSPG) for high affinity 
binding to their specific receptors (Marek et al. 2009). Four high-affinity 
receptors have been identified for the FGF family, in humans and mice, named 
FGFR1 to FGFR4. These receptors are type I transmembrane proteins with an 
extracellular ligand-binding domain with three immunoglobulin domains (I, II, and 
III), a transmembrane domain, and a split intracellular tyrosine kinase domain 
(Itoh 2007). 
 
FGF proteins bind to FGFR proteins and induce their dimerization and the 
phosphorylation of specific cytoplasmic tyrosine residues (Itoh 2007). The 
phosphorylation of FGFRs triggers activation of cytoplasmic signal transduction 
pathways. This activation results in the activation of several signal transduction 
pathways eliciting different cell responses (Itoh 2007). Phylogenetic analysis 
indicates potential evolutionary relationships in the gene family. Co-evolution 
has permitted the evolution of increased ligand-receptor specificity, enabling the 
formation of preferred ligand-receptor interactions (Itoh 2007). In addition, the 
alternative splicing of FGFRs has increased their functional diversity. Several 
alternative splicing events take place following transcription of FGFR1, FGFR2 
and FGFR3 and give rise to different isoforms with distinct functional properties 
(Marek et al. 2009). Of particular importance to FGF binding specificity is the 
third Ig loop, the N-terminal half of which is encoded by an invariant IIIa exon 




Olsen, & Ibrahimi 2005). The immunoglobulin-like domain III is an essential 
determinant of ligand-binding specificity (Itoh 2007). As a general rule, FGFRs 
encoding exon IIIb (FGFR IIIb) are expressed on epithelial cells, whereas the 
FGFRs encoding exon IIIc (FGFR IIIc) are expressed on mesenchymal cells 
(Mohammadi, Olsen, & Ibrahimi 2005). By contrast, the ligands for FGFR IIIb 
are often expressed in mesenchymal cells, whereas ligands for FGFR IIIc are 
expressed in epithelial cells (Marek et al. 2009;Itoh 2007). This establishes a 
paracrine mechanism of signalling between epithelia and mesenchyme that is 
critical to normal development and tissue homeostasis (Marek et al. 2009). 
 
1.3.2 FGF2 
The most studied member of the FGF family in asthma pathophysiology is 
FGF2, also known as basic FGF. This growth factor was first identified in bovine 
pituitary extracts and, together with FGF1, was named based on its capacity to 
stimulate the proliferation of the fibroblastic cell line NIH3T3 (Thomas 1987). 
FGF2 was previously known as basic FGF (bFGF) owing to its high isoelectric 
point (pI = 9.6), which results from its large number of basic residues. FGF2 is 
an 18 kD signal protein that varies little between organisms, typically exhibiting 
sequence homology in excess of 90 % (Nugent & Iozzo 2000). Concentrations 
of FGF2, a potent fibroblast mitogen, have been reported to be increased in BAL 
fluid in patients with mild asthma at baseline and further increased in the airways 
of individuals with allergic asthma after endobronchial allergen challenge 
(Redington et al. 2001;Shute et al. 2004). 
In view of the potentially important role for FGF2 in the pathogenesis of tissue 
remodelling in asthma, Shute et al used an immunohistochemical approach to 
compare the distribution of FGF2 and HSPG in bronchial tissue from patients 




and extracellular FGF2 immunoreactivity was detected in bronchial tissue from 
control and asthmatic subjects. Intracellular FGF2 was observed within bronchial 
epithelial cells and in cells within the subepithelial region (Shute et al. 2004). 
Extracellular FGF2 was seen in the pericellular matrix of endothelial cells and in 
the epithelial basement membrane. Quantitative analysis indicated a greater 
area of epithelial FGF2 immunostaining in asthmatic tissue than in control tissue 
(Shute et al. 2004). FGF2 is a mitogen for many cells including fibroblasts and 
endothelial cells- cell types that express CD34 and these cells may therefore be 
both a source and a target of FGF2 activity. FGF2 release is likely to contribute 
to the structural changes seen in the asthmatic airway, including fibroblast 
proliferation and angiogenesis (Shute et al. 2004). 
 
FGF2 has been shown to mediate a mitogenic response in mesoderm and 
neuroectoderm cells such as fibroblasts, osteoblasts, endothelial cells, and 
smooth muscle cells primarily through transmembrane receptors (Ornitz & Itoh 
2001). It is probably best known for its role in the growth and function of vascular 
cells (Nugent & Iozzo 2000). FGFs have the biological activity of stimulating the 
proliferation of fibroblasts and angiogenesis, which facilitates potential use in 
skin wound healing (Yun et al. 2010). Both FGF1 and FGF2 are known to be 
highly released by damaged endothelial cells and macrophages at wound sites, 
and if FGF2 activity is blocked, wound angiogenesis is almost completely 
impaired (Yun et al. 2010). Sources of FGF2 also include mast cells and T cells. 
FGF2 is also known to induce scar-free healing (Spyrou & Naylor 2002). Among 
the FGFs, application studies of wound healing and skin regeneration have 






FGFR1, also known as basic fibroblast growth factor receptor 1, and CD331, is 
a receptor tyrosine kinase whose ligands are members of the fibroblast growth 
factor family. FGFR1 has a molecular weight of 92 kDa and functions to promote 
mitogenesis in response to fibroblast growth factors. FGFR1 is predominantly 
expressed in the brain and in mesenchymal tissues in the embryo, in brain, 
bone, kidney, skin, lung, heart and muscle in the adult, but not in liver (Johnson 
& Williams 1993). The receptors for FGF1 and FGF2 were identified by cross-
linking of the two ligands to the receptors (Itoh et al. 1990). The cDNA for the 
FGF2 receptor was first isolated from a chicken embryo cDNA library (Itoh et al. 
1990).  
 
1.4 Structural Cells 
The ability of structural cells (epithelial cells, fibroblasts, smooth muscle cells 
and endothelial cells) to synthesise a wide array of inflammatory mediators 
including proinflammatory cytokines and chemokines implicate these cells as 
potential inflammatory effector cells in asthmatic airways (Figure 1.4)(Laberge & 
El Bassam 2004). The exact contribution of specific structural cell types to the 
overall production of mediators involved in inflammatory cell influx to the airways 
is unclear (Laberge & El Bassam 2004). Continuation of airway inflammation in 
asthma likely results from the coordinated expression of several cytokines and 
chemokines by different cell types working at different time points. 
 
Airways are embedded in the mechanically dynamic environment of the lung. In 
the adult lung, the mechanical environment is defined by a dynamic balance of 
surface, tissue, and muscle forces (Niimi 2011). Diseases of the airways 




well as the structure and mechanical behaviour of the airways (Niimi 2011). For 
instance, in asthma, activation of ASM abruptly changes the airway size and 
stress state within the airway wall (Tschumperlin & Drazen 2006). The folding of 
the airway wall into a rosette pattern during bronchoconstriction creates a 
complex stress field, with the highest stresses compressing the epithelial layer 
at the inner surface of the airway wall (Niimi 2011). The epithelial cells lining the 
airway possess the capacity to modulate the inflammatory environment of the 
airway wall, and produce factors that influence the recruitment, proliferation, and 
activity of fibroblasts and ASM cells (Tschumperlin & Drazen 2001). Especially, 
a prominent role has been identified for the epithelium in transducing 
mechanical stresses (Niimi 2011). A variety of in vitro studies have 
demonstrated that airway epithelial cells, along with lung fibroblasts and ASM 
cells, are responsive to mechanical stimuli (Niimi 2011). Airway epithelial cells 
exposed to compressive stresses equivalent to those occurring in the 
constricted airway increase expression of genes relevant to airway remodelling 
such as matrix metalloproteinase (MMP)-9, endothelins 1 and 2, TGF-β2, and 
increase the synthesis of fibronectin, collagen types III and V by cocultured 
fibroblasts (Tschumperlin & Drazen 2006;Tschumperlin et al. 2003). These 
findings demonstrate that mechanical stress may contribute to the remodelling 









Figure 1.4 Syntheses and secretion of cytokines, chemokines and growth factors 
















1.4.1 Airway Epithelial cells 
The epithelium of the lung is the first point of contact for inhaled pollutants, 
airborne allergens, and microorganisms (Bals & Hiemstra 2004). It plays an 
active role in immunity, through environmental sensing and pathogen detection, 
signalling to modulate both innate and adaptive immune responses, and direct 
antimicrobial activities (Kato & Schleimer 2007).  
The airway epithelium is pseudostratified, columnar, or cuboidal, and consists 
mostly of ciliated, undifferentiated, secretory and basal cells (Crystal et al. 
2008). The airway epithelium lies on a basement membrane, which provides an 
anchor to facilitate adhesion and migration of epithelial cells, regulates their 
phenotype and polarity, and separates them from the underlying mesenchymal 
tissue (Knight & Holgate 2003). Infiltrating inflammatory and immune cells can 
move freely through this membrane and between epithelial cells (Knight & 
Holgate 2003). 
The airway epithelium plays a vital role in protecting the human body from 
foreign particles. The tight junctions that fasten together epithelial cells prevent 
the passage of molecules between adjacent cells, forming a physical barrier that 
protects underlying tissues (Schneeberger & Lynch 1984). The mucociliary 
elevator system, consisting of mucus-secreting and ciliated cells, functions to 
effectively clear inhaled pollutants, allergens and microbes from the lungs (Mall 
2008). Recognition of inhaled particles by epithelial cells leads them to secrete 
mediators such as chemokines and cytokines to attract professional immune 
cells, but some of their secretions also show direct antimicrobial activity. These 
include short antimicrobial peptides such as defensins, and larger proteins such 





1.4.1.1 Airway epithelium in asthma pathogenesis  
A large body of work has focused on immunological aspects of asthma 
pathogenesis. There is evidence that the epithelium of asthmatics is 
fundamentally abnormal, with increased susceptibility to environmental injury 
and impaired repair mechanisms (Kicic et al. 2006). Consequently, asthmatic 
epithelium releases pro-inflammatory mediators as well as growth factors that 
will act on underlying fibroblasts, driving airway remodelling (Kicic et al. 2006). 
The primary role of the airway epithelium in asthma pathogenesis is supported 
by the finding that epithelial damage and airway remodelling may predate the 
onset of asthma symptoms (Busse et al. 1999). Furthermore, genetic 
association studies have identified strong links between asthma and genes 
expressed by cells of the airway epithelium and underlying mesenchymal tissue 
(Holgate et al. 2007). 
 
It has been suggested that the sub-epithelial fibrosis in asthmatic lungs may 
contribute to thickening of the airway wall, which in turn may result in 
physiological alterations such as airflow obstruction and AHR (Cohen et al. 
2007). Cohen et al evaluated if there are structural and functional differences in 
the airway epithelium in severe asthma associated with airway remodelling. It 
was observed that the epithelium was thicker in the subjects with severe, 
persistent asthma than in those with mild, persistent asthma and normal control 
subjects (Cohen et al. 2007). Epithelial cells, cytokines and growth factors 
amongst numerous cells and mediators appear to play a part in the remodelling 






The pulmonary epithelium is the first point of contact for inhaled environmental 
allergens and is increasingly implicated as a central player in the Th2 cell 
sensitisation process (Folkerts & Nijkamp 1998). The relationship between the 
pulmonary innate immune system and surrounding tissue is essential to the 
proximal events leading to Th2 mediated allergen sensitivity and there is now a 
growing appreciation of the contribution of innate immune system to asthma 
(Hammad & Lambrecht 2008). Epithelial cells influence dendritic cell function 
through direct cell-cell interaction and via the release of mediators (Hammad & 
Lambrecht 2008). Allergens such as house dust mite can directly or indirectly 
interact with the innate immune functions of airway epithelial cells (Hammad et 
al. 2009). Many allergens possess epithelial modulatory activity and increase the 
permeability of this barrier (Kalsheker et al. 1996). Indeed, inhaled allergens can 
directly stimulate epithelial cells to produce a range of mediators such as thymic 
stromal lymphopoietin (TSLP), IL-33, and IL-25 (Murdoch & Lloyd 2010). These 
mediators can direct a polarised Th2 cell effector response and further 
perpetuate the salient features of asthma (Murdoch & Lloyd 2010). 
 
1.4.2 Fibroblasts 
Fibroblasts are resident cells of the lungs, which provide structure to the tissue, 
and also play an active role in inflammation (Spoelstra, Postma, & Kauffman 
2001). Although they are regarded as fixed cells of connective tissue origin, they 
retain the capacity for growth and proliferation and are a pluripotent cell 
(Bousquet et al. 2000).  
Fibroblasts are the major type of mesenchymal cell present in the matrix of 
connective tissue. In addition to their structural role, fibroblasts make important 




various cytokines, matrix components and matrix-degrading enzymes 
(Spoelstra, Postma, & Kauffman 2001). 
 
Fibroblasts are able to produce many different chemokines and cytokines upon 
stimulation. These products can, in turn, activate or attract inflammatory cells, 
e.g. eosinophils, to the lung (Spoelstra, Postma, & Kauffman 2001). The major 
feature of lung fibroblasts is their participation in the maintenance of tissue 
integrity (Laberge & El Bassam 2004). Lung fibroblasts are involved in the repair 
process in response to inflammation by the release of a variety of extracellular 
matrix components such as elastin and fibronectin (Laberge & El Bassam 2004). 
In addition to contributing to airway remodelling, these cells may also play a role 
in the local regulation of immune and inflammatory responses via the expression 
of adhesion molecules (intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule 1 (VCAM-1)) involved in leukocyte recruitment into lung 
tissues, leading to the production of a large array of inflammatory cytokines and 
chemokines (Laberge & El Bassam 2004). Different tissues and even one and 
the same tissue contain fibroblasts of varying phenotypes (Sime et al. 1997). For 
instance, fibroblast cell lines derived from chronically inflamed tissue and tissues 
undergoing repair differ in significant ways from those obtained from normal 
tissues. These differences include the rate of cell proliferation, pattern of gene 
expression of matrix proteins and integrins, and cytokine production. 
 
1.4.2.1 Fibroblasts in asthma pathogenesis  
The remodelling in the airways as seen in asthma is largely a result of altered 
fibroblast behaviour (Spoelstra, Postma, & Kauffman 2001). Of particular 
interest in connection with asthma are myofibroblasts, which are contractile, 




contain, ie. desmin and alpha-smooth muscle actin (α-SMA) (Powell et al. 1999). 
An increased number of myofibroblasts beneath the reticular basement 
membrane has been reported in airways of patients with chronic asthma 
(Kohan, Breuer, & Berkman 2009). Benayoun et al found that the numbers of 
fibroblasts in the bronchial mucosal subepithelial compartment were increased 
in severe asthmatics compared with mild asthmatics and controls, leading to the 
conclusion that fibroblast accumulation is a selective determinant of severe 
persistent asthma (Benayoun et al. 2003). Activated fibroblasts or 
myofibroblasts may also be involved in the deposition of extracellular matrix and 
formation of airway fibrosis in asthma (Cai et al. 2008).  
Fibrocytes are progenitor cells in peripheral blood, which may migrate into the 
tissue and differentiate into fibroblast-like cells. In mild asthmatics an increased 
number of fibrocytes in tissue have been correlated with a thicker basement 
membrane (Nihlberg et al. 2006). In response to activation by the pro-
inflammatory cytokines IL-1β and TNF-α, fibroblasts synthesise and secrete a 
wide range of inflammatory mediators, including IL-6, IL-8, TGF-β, and FGFs 
(Osornio-Vargas et al. 1996).  
A number of mediators present at sites of inflammation act as chemoattractants 
for fibroblasts. PDGF and fibronectin have been demonstrated to recruit 
fibroblasts to inflammatory sites, as well as to activate these cells (Osornio-
Vargas et al. 1996). The proliferation of fibroblasts is stimulated by a variety of 
mediators, including cytokines, components of the extracellular matrix and 
granule proteins of eosinophils and mast cells (Sime et al. 1997). Accordingly, 
FGF, PDGF and TGF-β, which are produced by mesenchymal cells and 
activated macrophages, have all been shown to act as mitogens for fibroblasts 





Fibroblasts constitute a heterogeneous family of cells that express different 
phenotypic and functional features depending on their site of origin (Doucet et 
al. 1998a). For example, in human skin fibroblasts IL-4 is thought to increase 
DNA synthesis, collagen, fibronectin and tenascin deposition (Vita et al. 1995). 
Therefore, it is possible that some of the effects of IL-4 on asthmatic airway 
hyperresponsiveness can result from a direct and specific action of the cytokine 
on lung fibroblasts (Doucet et al. 1998a). 
 
1.4.3 Airway Smooth Muscle 
Smooth muscle cells are multifunctional mesenchymal cells. Changes, such as 
hypertrophy and hyperplasia in smooth muscle cells are well recognised 
features of airway remodelling in asthma (Laberge & El Bassam 2004). 
Alterations in the contractile and proliferative properties of the smooth muscle 
cells in airways are associated with several pulmonary disorders (Hirst et al. 
2004). These cells play the major role in regulating bronchoconstriction and 
relaxation in asthmatics. In these same patients, these cells proliferate, thereby 
increasing the total mass of smooth muscle in airway walls (Hirst et al. 2004). At 
the same time, smooth muscle cells are an important source of proinflammatory 
cytokines, chemokines and other growth factors and, moreover, they produce 
components of the extracellular matrix, including, MMPs and their inhibitors in 
tissues. Smooth muscle cells also express adhesion molecules and integrins, 
which act as receptors for most extracellular matrix proteins (Hirst et al. 2004). 
 
1.4.3.1 Airway Smooth Muscle in asthma pathogenesis   
Huber and Koesler were the first to describe an increase in ASM tissue in the 




a greater role in asthma patients than healthy individuals (Zou et al. 2008) and is 
the most significant cellular change contributing to airway wall remodelling 
(Lambert et al. 1993). Increased smooth muscle mass in asthma may be caused 
by the proliferative and growth inducing effects of cytokines (Laberge & El 
Bassam 2004). Multiple other mechanisms may contribute; including 
constitutional increases from birth caused by genetic, early life and 
environmental influences and decreased apoptosis/prolonged cell survival (Bai 
& Knight 2005). 
 
Animal studies suggest that repeated chronic allergen exposure, causing 
airways inflammation can increase smooth muscle mass along with other 
features of airway remodelling (Leigh et al. 2004). On the other hand, once 
established, persistent AHR is likely to depend on the persistence of increased 
ASM mass which has the potential to dominate the mechanical response of the 
remodelled asthmatic airway (Oliver et al. 2007), rather than the persistence of 
inflammation. It could therefore be argued that regulation of this remodelling is 
the most important therapeutic target especially for treatment of chronic, severe 
asthma. 
 
Pepe et al assessed airway remodelling by determining the area and integrity of 
the epithelium, the smooth muscle mass, and the distance between the 
epithelium and ASM on bronchial biopsy tissues (Pepe et al. 2005). It was found 
that ASM area was greater in subjects with severe asthma than in subjects with 
moderate asthma, and also the distance between the epithelial and ASM layers 
was less in the severe group than in the moderate group (Pepe et al. 2005). 
They came to a conclusion that smooth muscle alteration is the key structural 
change that distinguishes severe asthma from moderate asthma. This altered 




symptomatic when compared with subjects with moderate asthma (Pepe et al. 
2005). 
 
1.4.4 Endothelial cells 
Common to all vessels of the vasculature is the endothelium, which is a single 
layered sheet of squamous, polarised cells that are primarily responsible for all 
signalling and transportation from blood to tissue and vice versa (Cines et al. 
1998). 
 
Different types of endothelial cells have been isolated and cultured to 
understand the biology and pathobiology of the vasculature and the angiogenic 
response (Boisen et al. 2010). The cells most widely used in in vitro studies are 
isolated from human umbilical vein, HUVEC, which show a characteristic 
cobblestone shape when cultured. HUVEC are the most extensively studied 
endothelial cell type, primarily because they are relatively easy to isolate and 
culture (Boisen et al. 2010). In vivo, angiogenesis is mediated by the 
microvasculature and the angiogenic response of human microvascular 
endothelial cells (HMVEC), which has been suggested to be stronger than that 
of HUVEC because of differing expression of matrix metalloproteases (Jackson 
& Nguyen 1997). However, HMVEC are generally more fastidious in their culture 
requirements than HUVEC making long-term culture more challenging (Boisen 
et al. 2010). 
 
Functional studies of endothelial cells have been carried out in culture, as 
endothelial cells cultured in the presence of an ECM organise themselves into 
tube-like structures (Boisen et al. 2010). This response is seen as a mimic of 




as a simple in vitro angiogenesis assay (Boisen et al. 2010). As expected for 
endothelial cells, low passage HUVEC form tube-like structures when cultured 
on top of gels formed by ECM proteins such as collagen-1 or Matrigel (Unger et 
al. 2002). However, such studies have not been reported for microvascular 
endothelial cells, although these cells are directly involved in angiogenesis 
(Boisen et al. 2010). While endothelial cells in vivo are normally quiescent, 
cultured endothelial cells are maintained in an artificially activated state 
characterised by extensive proliferation (Laberge & El Bassam 2004). Airway 
endothelial cells are a source of chemokines that may contribute to the 
recruitment and the activation of basophils, eosinophils and lymphocytes into the 
airways (Laberge & El Bassam 2004). 
 
1.4.4.1 Endothelial cells in asthma pathogenesis 
Vascularity is an important component of the remodelling process in airway 
disease and increased vascularity, angiogenesis, is likely to occur in response to 
chronic inflammation (Li & Wilson 1997). Increased angiogenesis in the airways 
of asthmatics is well reported and is now considered to be another of the major 
components of airway remodelling in asthma (Li & Wilson 1997). Stimulation of 
angiogenesis is performed by various angiogenic proteins, including several 
growth factors. The list of pro-angiogenic cytokines and growth factors is 
extensive and these factors are secreted by inflammatory cells (mast cells and 
macrophages), smooth muscle and fibroblasts. The principal mediators 
implicated in angiogenesis and thus increased in asthma are vascular 
endothelial growth factor (VEGF), TNF-α and FGF2 (Damore 1992). 
In healthy individuals, up to 10% of a bronchial biopsy section may consist of 
vessels with over 500 vessels/mm2, whereas in an asthmatic biopsy up to 17% 




Wilson et al. suggested that the angiogenic process in asthma could be due to 
recurrent inflammatory episodes, or a response to the two- to threefold increase 
in tissue volume that occurs in the airways due to remodelling (Wilson & Stewart 
1999). Blood vessel size has also been shown to be larger in the asthmatic 
airway (Li & Wilson 1997). Cross-sectional measurements of blood vessels 
showed that over 19% of blood vessels in the asthmatic airway to have an area 
greater than 300μm2, compared to 12% in non-asthmatic airways (Li & Wilson 
1997). 
 
1.5 Th2 cytokines 
1.5.1 IL-4 
IL-4 is a 15-kd monomer (129 amino acids) produced by Th2 cells, basophils, 
mast cells, and eosinophils (Akdis et al. 2011). IL-4 is a major stimulus for Th2-
cell development; it also suppresses Th1-cell development and induces IgE 
class switching in B cells (Kuhn, Rajewsky, & Muller 1991). A pleiotropic 
cytokine, IL-4 regulates allergic conditions (Akdis et al. 2011). 
IL-4 increases the expression of class II MHC molecules in B cells, upregulates 
B-cell receptors, increases expression of CD23, prolongs lifespans of T and B 
cells in culture, and mediates tissue adhesion and inflammation. There are 2 
types of IL-4 receptors (IL-4Rs). Type I IL-4R binds only IL-4 and consists of 2 
receptor chains: IL-4Rα (CD124) and the common γc (CD132). Type II IL-4R 
binds IL-4 and IL-13 and consists of the IL-4Rα and the IL-13Rα1 chains (Wang 
et al. 2009). IL-4 and IL-4Rα knockout mice have defects in Th2-cell 
differentiation and reduced serum levels of IgG1 and IgE (Kuhn, Rajewsky, & 





Antibody to IL-4 initially appeared to be a promising strategy for treatment of 
asthma. In preclinical testing, monoclonal anti-IL-4 blocked development of 
specific IgE and AHR to ovalbumin in mice, but did not abrogate eosinophilia 
(Corry et al. 1996). Newer agents such as Pitrakinra, a mutant protein which 




IL-13 is a 4-helix bundle protein expressed by activated Th2 cells, mast cells, 
basophils, eosinophils, and natural killer T cells (Akdis et al. 2011). IL-13 shares 
many biological activities with IL-4 (de Vries 1998). This is due to the fact that IL-
13- and IL-4-receptor complexes share the IL-4Rα-chain, which is important for 
signal transduction (de Vries 1998). Its receptors are IL-13Rα1 and IL-13Rα2, 
and signalling occurs via the IL-4R complex type II, which consists of IL-4Rα 
and IL- 13Rα1 (Akdis et al. 2011). IL-13 activates many of the same signal 
transduction pathways as IL-4 and induces IgE production. It also activates and 
recruits mast cells and eosinophils and promotes their survival. 
 
In single-nucleotide polymorphism studies, a combination of relevant 
polymorphisms in the IL-4 and IL-13 signalling pathways has been associated 
with a 16.8-fold risk of asthma. Polymorphisms in IL-13 pathways alone were 
associated with increased risk of asthma exacerbations in children and elevated 
blood total IgE and eosinophils (Hunninghake et al. 2007). In animal “asthma” 
models, IL-13 knockout mice produce less IL-4, IL-5, IL-10, and IgE and fail to 
develop goblet cell hyperplasia (McKenzie et al. 1998). IL-13Rα1 knockout mice 






Pulmonary delivery of IL-13 to mice (Grunig et al. 1998) or targeted 
overexpression of IL-13 in the lung induce multiple correlates of asthma 
pathology, including airway eosinophilia, mucus cell metaplasia, airway fibrosis, 
eotaxin production and AHR (Zhu et al. 1999). Despite their shared activities, 
studies in animal models have pointed to a preferential role for IL-13 over IL-4 in 
driving asthma pathology (Grunig et al. 1998). In an inducible model of 
transgenic lung IL-13 expression, fibrosis was initiated upon IL-13 induction and 
persisted even following withdrawal of the cytokine, demonstrating that IL-13 
has the capacity to drive irreversible remodelling processes in the asthmatic 
lung (Fulkerson et al. 2006). 
 
As T cells do not express functional IL-13 receptors, IL-13, in contrast to IL-4, 
fails to induce Th2-cell differentiation, which is one of the hallmarks of the 
allergic response. However, IL-13 is required for optimal induction of IgE 
synthesis, especially in situations in which IL-4 production is low or absent (de 
Vries 1998). On the other hand, IL-13 inhibits proinflammatory cytokine and 
chemokine production in vitro and has potent anti-inflammatory activities in vivo 
(de Vries 1998). 
 
Both IL-4 and IL-13 can mediate direct activation of lung fibroblasts in vitro, 
inducing eotaxin release, TGF-β production, and collagen gene expression 
(Doucet et al. 1998b). 
 
In summary, it is clear that airways remodelling is an infinitely complex process. 
Although at least partly inflammation driven, it may also partly be driven simply 
by mechanical stress on the airways and may be responsible for lasting airways 




including epithelial, endothelial, smooth muscle and fibroblast/mesenchymal 
cells are likely involved in remodelling and interact in complex ways through 
contact and the production of growth and other mediators.  
 
Anaphylatoxins have also been implicated, at least circumstantially, in asthma 
pathogenesis and it is now clear that structural airways cells, as well as 
inflammatory cells express their receptors, raising the possibility that they are 
involved in the remodelling process. The overall aim of the studies described in 
this thesis is to probe this question by investigating effects of anaphylatoxins on 




1.6 Aims and Hypotheses 
A considerable amount of literature has been published on asthma and the 
airways. It is only during the past 20 years or so, however, that information has 
become available on the impact of the complement system on asthma. 
Numerous studies have attempted to explain the role of complement 
components in the asthmatic airway using patients as well as animal models. So 
far, however, these attempts to establish a link between asthma and 
anaphylatoxins are somewhat controversial, circumstantial and inconclusive.  
 
The objectives of the studies presented here aim to examine the expression of 
certain components of the complement pathway and its receptors in the 
asthmatic bronchial epithelium and on structural cells of the airways, investigate 
the effects of anaphylatoxins on structural cells of the airways which may be 
relevant to remodelling, and compare these with the effects of established 
remodelling mediators, in particular the cytokines IL-4 and IL-13.  
 
 
It was hypothesised that: 
 There is elevated expression/deposition of the complement fragments 
C3, C3d and C5b-9 in the bronchial mucosa of asthmatics compared to 
controls 
 There is elevated expression/deposition of the complement fragments 
C3, C3d and C5b-9 in the bronchial mucosa of atopic asthmatics 
following bronchial allergen challenge 
 C3a and C5a play a role in effecting airway remodelling by acting on 




smooth muscle cells to induce remodelling changes or production of 
remodelling mediators.  
 
The specific aims of this thesis were to: 
1) Measure expression/deposition of C3, C3d and C5b-9 fragments in the 
bronchial epithelium, submucosa, ASM and glands of asthmatics & controls 
 
2) Detect expression of C3aR and C5aR in the bronchial epithelium, 
submucosa, ASM and glands of asthmatics & controls, and in addition to study 
the effects of allergen challenge of atopic asthmatics 
 
3) Detect expression of C3aR and C5aR on structural cells of the airway 
involved in remodelling propagated in vitro 
 
4) Investigate C3a and C5a-stimulated production of remodelling mediators 
(FGFs, IL-8) by these cells at the mRNA and protein level 
 
5) Assess biological functions of C3a and C5a on those structural cell types 
which may be relevant to remodelling (i.e. by proliferation assays) 
 
This would allow for a better insight into the role of anaphylatoxins, their 










Chapter 2:  Materials & 
Methods 
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2.1 Cell culture  
2.1.1 Epithelial cell culture 
2.1.1.1  A549 
A549 cells (adenocarcinomic human alveolar basal epithelial cells) were 
obtained from the American Type Culture Collection. Cells were expanded in 75 
cm2 tissue culture flasks (Thermo Fisher Scientific, UK) containing 15 ml 
Dulbecco’s Modified Eagle Medium ((DMEM), Invitrogen) supplemented with 10 
% foetal bovine serum ((FBS), Invitrogen) and 1 % penicillin-streptomycin 
solution (Invitrogen). Cell cultures were incubated at 37 C in a humidified 
incubator with 5 % CO2 in air. Fresh medium was added after every two days of 
culturing. Cells were routinely subcultured or passaged (following trypsinisation; 
see section 2.1.5) after reaching confluence. Cultures of reasonable confluency, 
around 80 %, were used for all studies. A549 cells used were all between 
passages 2-3.  
 
2.1.1.2 BEAS-2B 
BEAS-2B (American Type Culture Collection) cells were cultured in the same 
way as A549 cells (see section 2.1.1.1). BEAS-2B cells are adenovirus-
transformed cells established from normal human bronchial epithelium. 
 
2.1.1.3 HBEpC 
Human Bronchial Epithelial Cells (HBEpC) were purchased from Promocell. 
These cells are isolated from the surface epithelium of human bronchi and stain 
positively for cytokeratin. HBEpC were grown in 75 cm2 tissue culture flasks 
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(Thermo Fisher Scientific) pre-coated with collagen I (5 mg/ml; Invitrogen) in 
ascetic acid (0.02 M) by culturing for at least 1 hour at 37 C, with 5 % CO2 in a 
humidified incubator. The cells were cultured in Airway Epithelial Cell Growth 
Medium Kit, which consists of Basal Medium and a Supplement Pack. The 
growth medium was formulated to consist of 2 % serum and 1 % 
antibiotics/antimycotics. Fresh medium was added after every two days of 
culturing. Cells were routinely subcultured (following trypsinisation; see section 
2.1.5) after reaching confluence, and cultures of reasonable confluency, around 
80 %, were used for all studies. HBEpC used were between passages 2-4. 
 
2.1.2 Fibroblast cell culture 
2.1.2.1 MRC-5 
Human lung fibroblasts (MRC-5, American Type Culture Collection), a 




Human Pulmonary Fibroblast Cells (HPFC) which are isolated from human lung 
tissue were purchased from Promocell. According to Promocell the HPFC’s 
have been tested as fibroblast specific surface antigen positive. They are often 
used for studying lung tissue repair, tissue remodelling after injury, or the 
response after pulmonary inflammation. The HPFC 75 cm2 tissue culture flasks 
and 12-well plates (Thermo Fisher Scientific) were pre-coated with collagen I (5 
mg/ml; Invitrogen) in acetic acid (0.02 M) by culturing for at least 1 hour at 37 
C, with 5 % CO2 in a humidified incubator for better cell adherence and cell 
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growth. HPFC were grown and cultured just like MRC-5 and A549 cells (see 
section 2.1.1). Fresh medium was added after every two days of culturing. Cells 
were routinely subcultured or passaged (following trypsinisation; see section 
2.1.5) after reaching confluence, and cultures of reasonable confluency, around 
80 %, were used for all studies. Fibroblast cells used were at passage 2. 
Primary cultures of human lung fibroblasts maintain their phenotypic 
characteristics in vitro throughout a substantial number of passages.  
 
2.1.3 Smooth muscle cell culture 
2.1.3.1 HBSMC 
Human Bronchial Smooth Muscle Cells (HBSMC; also referred to as HSMC) 
were purchased from Promocell and grown and cultured in 75 cm2 tissue culture 
flasks (Thermo Fisher Scientific) with Smooth Muscle Basal Medium (Promocell) 
formulated to contain 2 % v/v serum (FCS). Fresh medium was added after 
every two days of culturing. Cells were routinely subcultured (following 
trypsinisation; see section 2.1.5) after reaching confluence, and cultures of 
reasonable confluency, around 80 %, were used for all studies. Smooth muscle 
cells used were between passages 2-3. HBSMC are isolated from the bronchi of 
single donors and stain positive for smooth muscle α-actin. These cells are 
suitable for in vitro studies of asthma and other pulmonary diseases. According 
to Promocell, HBSMC have been tested smooth muscle α-actin positive, von 
Willebrand factor (vWF) negative and CD90 negative. 
 
  63
2.1.4 Endothelial cell culture 
2.1.4.1 HUVEC 
Human umbilical vein endothelial cells (HUVEC) obtained from Promocell were 
cultured in Endothelial Cell Basal Medium (Promocell) supplemented with 
Endothelial Growth Medium singlequots (Promocell) and FBS (2 % final 
concentration). To promote HUVEC attachment and growth, all culture surfaces 
were pre-coated with 5 mg/ml collagen I (Invitrogen) in acetic acid (0.02 M) by 
culturing for at least 1 hour at 37 °C with 5 % CO2 in humidified air. Fresh 
medium was added after every two days of culturing. Cells were routinely 
subcultured by trypsinisation (see section 2.1.5), and cultures of around 70-80 % 
confluency were used for all studies. HUVEC cells used were all between 
passages 2-3.  
 
2.1.4.2 HPMEC 
Human Pulmonary Microvascular Endothelial Cells (HPMEC) were purchased 
from Promocell. HPMEC were cultured in Endothelial Cell Growth Medium 
(Promocell), which is a low serum medium optimized for the cultivation of 
endothelial cells from blood vessels. This medium was chosen as it does not 
contain VEGF. Generally, VEGF leads to higher endothelial cell proliferation in 
culture. It also has multiple effects on the cell metabolism, which may interfere 
with certain experimental setups. HPMEC were cultured in 75 cm2 tissue culture 
flasks pre-coated with 1 % gelatin (Sigma-Aldrich, St. Louis, MO). The cells 
were grown in an atmosphere of 5 % CO2 at 37 °C and routinely subcultured by 
trypsinisation (see section 2.1.5) after they reached confluence.  The cells were 
allowed to grow till they reached 80 % confluence before treatment. HPMEC 
cells used were all between passages 3-5.  
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Batches of HPMEC are isolated from the lung of a single donor. According to the 
manufacturer the cells are routinely analyzed by immunofluorescent staining: 
they stain positive for CD31 and vWF, and negative for smooth muscle α-actin. 
Because of their location at the interface between the circulating fluid in the 
lumen and the surrounding tissue, microvascular endothelial cells are highly 
active and closely involved in numerous physiological processes. The lung has a 
vast endothelial surface area, which is essential for the exchange of gases. 
HPMEC are most appropriate for studying human lung diseases. 
 
2.1.5 Cell subculture 
Cells were subcultured by trypsinisation. Cells were passaged such that the 
monolayers never exceeded 75-90 % confluency. Growth medium was 
aspirated from the culture flasks. Cells were washed in Hanks balanced salt 
solution ((HBSS), Invitrogen), followed by incubation with 0.05 % trypsin 
supplemented with 0.53 mM ethylenediaminetetraacetic acid solution salt 
((EDTA.4Na): (1X Trypsin-EDTA), Invitrogen) for 3-5 minutes. Detachment of 
cells was confirmed by microscopy. In the case of A549 and MRC-5 cells 
trypsinisation was stopped by the addition of 2 times the volume of growth 
medium (supplemented DMEM, Invitrogen); for HBEpC, HSMC and the 
endothelial cells, trypsinisation was stopped by the addition of an equal volume 
of Trypsin Inhibitor (Invitrogen). The cells were transferred to a 50 ml Falcon 
tube and centrifuged at 200 x g for 5 minutes and resuspended in 1 ml of their 
respective growth medium. Cell viability was examined by exclusion of Trypan 
Blue (Sigma-Aldrich) in a haemocytometer visualised by light microscopy for 
manual cell counting.  
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2.1.6 Cell starvation 
For gene expression and enzyme-linked immunosorbent assay (ELISA) 
experiments cells were subcultured and seeded on 12 well plates (Thermo 
Fisher Scientific) at a density of 0.1 x 104cells/ml in a total volume of 1 ml per 
well. For western blot experiments cells were seeded on 6 well plates (Thermo 
Fisher Scientific) at a density of 2.5 x 104cells/ml in a total volume of 1.5 ml per 
well. 
 
Prior to treatment, the cells were maintained in serum free medium for 24 hours. 
A549 and MRC-5 cells were maintained in a 1:1 Nutrient Mixture of Ham’s F-12 
Medium (Sigma Aldrich) and DMEM (Invitrogen) supplemented with 1% 
penicillin-streptomycin solution (Invitrogen). HBSMC, HBEpC, HPMEC, HPFC 
and HUVEC were all maintained in their respective growth medium with reduced 
serum concentration (0.5% FBS, Promocell). 
 
2.1.7 Cell treatment 
Cells were treated with various agents following characterisation of time course 
and concentration responses. Time points selected for measurement of RNA 
expression were 4, 8 and 24 hours, while time points tested for protein 
expression were 24, 48 and 72 hours. The serum-free and low-serum cultures 
were stimulated with different cytokines: recombinant human TNF-α (R&D 
Systems, Minneapolis, MN USA) at 10ng/ml, recombinant human IL-4 (R&D 
Systems, Minneapolis, MN USA) at 10 ng/ml, recombinant human IL-13 (R&D 
Systems, Minneapolis, MN USA) at 10 ng/ml, and anaphylatoxins: human 
complement proteins C3a and C5a (Fitzgerald Industries International, Inc) at a 
concentration range of 10-10 M to 10-7 M. C3a and C5a proteins are prepared 
from normal human serum, with the concentration of the proteins in serum being 
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approximately 1.25 +/- 0.52 mg/ml. According to the manufacturer the products 
had been tested at serum donor level by FDA approved methods. The time 
points and concentrations used were based on existing literature.  On the last 
day of culture, the total cell culture lysate and culture supernatant were 
separately harvested. All culture supernatant samples were centrifuged to 
remove cellular debris then divided into 200-300 µl aliquots and stored at -20 C 
until used. The experiments with each of the structural cell types were repeated 
three to five times. 
 
2.2 Immunohistochemical Studies 
2.2.1 Patients & Study Design 
The expression of complement components and FGF2 was investigated in the 
bronchial mucosa of asthmatics and controls. Bronchial biopsies were obtained 
at fibreoptic bronchoscopy from controls and asthmatics. Asthma was defined as 
a history of typical symptoms and ≥ 12% reversibility of the PEF/FEV1 and/or 
methacholine PC20 ≤ 8mg/ml in the year prior to the study. Asthmatics were 
stratified for disease severity. Biopsies were also obtained from mild atopic 
asthmatics before and 24 h after bronchial allergen challenge with an allergen to 
which they were sensitised according to a standard protocol (Kariyawasam et al. 
2007). Patient characteristics are described in Table 2.1. All patients were 
recruited through the Department of Asthma, Allergy and Respiratory Science at 
Guy’s Hospital. The study was approved by the Guy’s (London Bridge) 
Research Ethics Committee and all subjects provided written, informed consent 
to participate in the studies and to have their tissues stored anonymously in our 















































































Table 2.1 Patient Characteristics. Data are expressed as the median (range). The mild 




2.2.2 Biopsy Sample Preparation 
Biopsies were OCT processed. For OCT processing, bronchial biopsies were 
fixed immediately in freshly prepared 4 % paraformaldehyde (PFA; BDH, Poole, 
UK) in phosphate-buffered saline (PBS), pH 7.4 for 2 hours. 4 % PFA in 0.1 M 
phosphate buffer is one of the common solutions used for 
immunohistochemistry. The biopsies were then washed with 15 % sucrose 
(Sigma Chemical CO, Poole, UK) in PBS, embedded in OCT compound and 
snap-frozen.  Sections were cut from biopsies at a thickness of 6 µm using a 
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cryostat, further air-dried for 1 hour at 37 °C, wrapped in foil and stored at -80 °C 
until use. 
 
2.2.3 Complement IHC ex vivo 
Immunohistochemistry (IHC) was performed on tissue sections. Optimal 
concentrations of all antibodies used were determined in pilot experiments. IHC 
staining of biopsies was performed using the peroxidase anti-peroxidase (PAP) 
method. The PAP method is a further development of the indirect staining 
method. The indirect technique involves an unlabelled primary antibody (first 
layer) which reacts with the tissue antigen and a labelled secondary antibody 
(second layer) which reacts with the primary antibody. The secondary antibody 
recognises the immunoglobulin of the animal species in which the primary 
antibody has been raised. This method ensures improved signal amplification 
through several secondary antibody reactions with different antigenic sites on 
the primary antibody and thus is a more sensitive method. The second layer 
antibody can be labelled with a fluorescent dye (indirect immunofluorescence) or 
with an enzyme such as a peroxidase or alkaline phosphatase. The PAP 
method involves adding a layer which is an antibody to peroxidase, coupled with 
peroxidase, making a very stable peroxidase anti-peroxidase complex. This 
complex acts as a third layer antigen, greatly increasing the sensitivity of the 
method because the peroxidase molecule is not chemically conjugated to the 
anti-Ig, but immunologically bound and loses none of its activity. It also allows 
for a much higher dilution of the primary antibody. The peroxidase is then 
developed by DAB or other substrates to produce a colorimetric end product.  
 
An initial blocking step was performed to block endogenous peroxidase in the 
tissue using hydrogen peroxide (H2O2; 1:30), made up in a 3 molar solution of 
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sodium nitrite (made in PBS). Bronchial tissue was blocked for 40 minutes and 
then the slides were washed in PBS twice for 5 minutes each time. The slides 
were then incubated overnight at room temperature with the control and primary 
antibodies (Table 2.2), which were made up using 5% normal human serum (in 
PBS). The slides were washed twice in PBS for 5 minutes each time, and then 
the monoclonal mouse antibody labelled slides were treated with the second 
layer rabbit anti-mouse (1:30; DakoCytomation, Inc) in 5 % serum in PBS for 30 
minutes whilst the rabbit (anti-C5b-9) slides were treated with the second layer 
mouse anti-rabbit (1:50; Dako) in 5 % serum in PBS for 30 minutes. After a 
further wash in PBS for 5 minutes twice, the slides were incubated with the third 
layer:  mouse anti-C3, C3d, C3aR and C5aR slides were treated with mouse 
PAP (1:50; Jackson ImmunoResearch Laboratories, Inc USA) for 30 minutes,  
whilst rabbit anti-C5b-9 was treated with rabbit PAP (1:50; Jackson 
ImmunoResearch Laboratories, Inc USA) for 30 minutes. The PBS washing step 
was repeated again after which the sections were developed with DAB (Sigma) 
in the dark for 10-20 minutes. During the developing period the sections were 
monitored periodically by eye and under a microscope. After sufficient 
developing the slides were washed in water for 10 minutes and counterstained 
with Mayer’s Haematoxylin (Sigma-Aldrich) for 2 minutes. This was washed off 
with water. The slides were then air-dried and the sections mounted under 
coverglasses using DPX (BDH). 
 
Staining and measurement of area were measured objectively using a digital 
analysis programme (Zeiss KS300 3.0) linked to an Olympus microscope. 
Sections were observed at x20 magnification. Geometric calibration (in µm) and 
light were adjusted. Overall expression of complement components followed by 
their expression on various cells was reported. This was done by outlining the 
individual tissue cells using the above programme and then subtracting the 
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stained areas from total areas measured. For example, the epithelium of the 
bronchial biopsy was drawn around to obtain a total area percentage. The 
programme determines the positive staining area as a ‘brown’ area percentage 











 1:50 Santa Cruz Biotech 
Mouse anti-C3d 
 1:25 AbD Serotech 
Rabbit anti-C5b-9 
 1:100 Abcam 
Mouse anti-C3aR 
 1:50 Abcam 
Mouse anti-C5aR 
 1:40 AbD Serotech 
 
Table 2.2 Primary antibodies used for IHC. 
 
 
2.2.4 FGF2 IHC ex vivo 
FGF2 immunoreactivity was measured in sections of bronchial biopsies from the 
same patients (see Table 2.1) according to the protocol described above 
(section 2.2.3). The primary layer was rabbit polyclonal anti-FGF2 (1:50; 
Abcam); the secondary layer was mouse anti-rabbit (1:50; Dako) and the tertiary 
layer was rabbit PAP (1:50; DakoCytomation). 
Objective, quantitative measurement of the total stained cells per unit area was 
performed as before using a digital analysis programme (Zeiss KS300 3.0) 
linked to an Olympus microscope. The numbers of positively stained cells were 
counted separately in the epithelium and submucosa and their total surface 
areas in each section were measured under x40 magnification. Results were 
expressed as the numbers of positive cells per unit area. 
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2.2.5 ICC in vitro 
Immunocytochemistry (ICC) was performed on cultured structural cells of 
various types. Cells were grown as described in the cell culture section 2.1 and 
seeded at 20,000 cells per chamber in four-chamber slides (VWR International). 
The cells were allowed to reach confluence after which they were gently washed 
in PBS and then fixed for 10 minutes in 4 % PFA then washed in PBS twice. The 
chamber slides were stained with the primary layer, mouse monoclonal C3aR 
(1:50; Abcam) and mouse monoclonal C5aR (1: 40; Abcam) diluted in 5 % 
normal human serum in PBS. Isotype-matched control antibodies were used as 
a negative control in the experiments. Incubation was overnight at room 
temperature. The slides were washed twice in PBS for 5 minutes each time and 
then treated with the second layer rabbit anti-mouse (1:30; DakoCytomation) in 
5 % serum in PBS for 30 minutes. The slides were washed twice again in PBS 
for 5 minutes each time, and then treated with the third layer mouse PAP (1:50; 
Jackson ImmunoResearch Laboratories) for 30 minutes. The PBS washing step 
was repeated again after which the sections were developed with DAB (Sigma) 
in the dark for 10-20 minutes; washed with water and then counterstained with 
Mayer’s Haematoxylin (Sigma-Aldrich) and mounted using glycergel. The cells 
were viewed and photographed with a Zeiss Axioskop 2 microscope equipped 
with appropriate filters.   
 
2.3 Cell proliferation assay 
Cell proliferation was assayed using the CellTiter 96® Aqueous Assay 
(Promega, USA). Cells were plated out 5000 cells per well in duplicate in 96-well 
flat-bottomed tissue culture plates (Costar, Cambridge, MA), allowed to adhere, 
serum starved for 16 hours and then exposed to various mediators: TNF-α (10 
ng/ml; R&D Systems), IL-4 (10 ng/ml; R&D Systems), IL-13 (10 ng/ml; R&D 
  73
Systems) and C3a and C5a (10-9 M to 10–7 M; Fitzgerald Industries International) 
in the respective cell growth medium. Aliquots of cells were exposed for 24 
hours, 48 hours and 72 hours, after which a MTS/PMS solution (20 l) was 
added to the media wells. The cells were then incubated at 37 C in a humidified 
incubator with 5 % CO2 in air for a further 3.5 hours. Results were read on a 
microplate reader at the test wavelength of 450 nm. The MTS assay is a 
colorimetric assay for measuring the activity of enzymes that reduce MTS dye to 
formazan dyes, giving a purple colour. It allows the assessment of proliferation 
of cells. 
 
2.4 Gene Expression Studies 
2.4.1 Extraction of cellular RNA 
Samples of typically 100,000 cells were harvested in buffer RLT. Buffer RLT 
contains the chaotropic agent guanidine isothiocyanate and the denaturant β-
mercaptoethanol (Sigma), and is used to lyse cells or tissue while protecting 
ribonucleic acid (RNA) via deactivation of RNase enzymes. It preserves RNA for 
subsequent analysis. Lysed cells were collected from the culture plates using 
cell scrapers (Thermo Fisher Scientific, Waltham, MA), and collected into 0.5 ml 
microfuge tubes. All samples were stored at -80 °C until RNA extraction. 
 
All RNA extractions were performed using the RNeasy Mini Kit with QIAshredder 
(Qiagen, Inc), following the manufacturer’s protocol, including the optional 1 
minute final spin, eluting RNA in 30 μl RNase-free water. RNA quality and yield 
were determined using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific, Wilmington, DE). 
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2.4.2 Reverse Transcription 
Total RNA (500 ng) was reverse-transcribed in a volume of 40 µl (Table 2.3). 
RNA extracts were first incubated with 0.2 µg Random Hexamer (Bioline) at 70 
°C for 5 minutes and allowed to cool down to room temperature. A master mix 
containing 5X Reaction Buffer (MBI Fermentas), dNTP mix (10 mM; MBI 
Fermentas), and Ribolock Inhibitor (40 u/µl; Fermentas) was then added and the 
mixture incubated at room temperature for 5 minutes. Revert-Aid™ Reverse 
Transcriptase (200 u/reaction; Fermentas Life Sciences) was then added and 
the reaction mix subsequently incubated using a PTC-200 Thermal Cycler (MJ 
Research) at room temperature for 10 minutes; 42 °C for 1 hour; and then at 70 
°C for 10 minutes to stop the reaction. The reverse transcription reaction 













RNA 500ng  
Random Hexamer 8 µl  
Deionised water Upto 25 µl  
5X Reaction Buffer 8 µl  
dNTP mix 4 µl  
Ribolock Inhibitor 0.5 µl  
Deionised water 1.5 µl  
Revert-Aid™ Reverse Transcriptase 1 µl  
Total 40 µl  
 




2.4.3 Real-Time Quantitative PCR 
Primer sets to examine gene expression by real-time quantitative PCR (qPCR) 
were purchased from the Gene Expression Inventoried Assays selection 
(Applied Biosystems) (Table 2.4). Aliquots (2.5 µl) of the diluted cDNAs were 
subjected to PCR in 15 µl reactions with 2X Taq Master Mix (Applied 
Biosystems), 18S rRNA (Applied Biosystems), and the specific primer/probe set 
in 384 well plates. Q-PCR was carried out at 50 °C for 2 minutes, 95 °C for 10 
minutes, 95 °C for 15 seconds, and 60 °C for 1 minute for 50 cycles using an 
ABI Prism 7900HT Thermal Cycler (Applied Biosystems). All messenger 
(m)RNA species were measured in triplicate samples, repeated at least three 
times and expressed in relation to the human housekeeping gene, 18S mRNA 
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levels. Results were analysed using SDS 2.1 Software (Applied Biosystems), 
and data presented as “Relative Expression.” 
 
Real-time PCR monitors the fluorescence emitted during the reaction as an 
indicator of amplicon production at each PCR cycle (in real time) as opposed to 
the endpoint detection. The hydrolysis probe (Taqman) technique was used 
here where the probe is conjugated with a quencher fluorochrome, which 
absorbs the fluorescence of the reporter fluorochrome as long as the probe is 
intact. However, upon amplification of the target sequence, the hydrolysis probe 
is displaced and subsequently hydrolyzed by the Taq polymerase. This results in 
the separation of the reporter and quencher fluorochrome and consequently the 
fluorescence of the reporter fluorochrome becomes detectable. During each 
consecutive PCR cycle this fluorescence will further increase because of the 























































2.5 Protein Expression Studies 
2.5.1 BCA Assay 
Total protein concentrations in samples were determined using a BCA Protein 
Assay kit (Thermo Scientific) following the manufacturer’s instructions: 10 µl of 
each standard and unknown samples were pipetted into microplate wells in 
duplicate. 200 µl of working reagent were added to each well with gentle mixing 
of the plate. The plate was then covered and incubated at 37 C in a humidified 
incubator with 5 % CO2 in air for 30 minutes and then cooled to room 
temperature. The absorbance was measured at or near 562 nm on a plate 
reader. 
 
2.5.2 Protein extraction from cultured cells 
Cells were rinsed in ice cold PBS and lysed in ice cold RIPA buffer (1 % Nonidet 
P-40, 0.5 % deoxycholate, 0.1 % SDS in PBS) containing a protease inhibitor 
cocktail (Roche).  For a 12-well plate 60-100 μl of buffer were used per well. The 
cells were incubated with the lysis buffer for 5 minutes on ice and then scraped 
using a sterile cell scraper (Thermo Fisher Scientific); collected and transferred 
in a microfuge tube and incubated a further 30 minutes on ice. After that the 
samples were sonicated for 5-8 seconds and incubated on ice for 30 minutes. 
Finally, the samples were centrifuged at 12,000 x g for 5 minutes at 4 oC to 
pellet the cell debris; the supernatant was carefully collected and stored at -20 






Concentrations of IL-6, IL-8, FGF2, thymus- and activation-regulated chemokine 
(TARC) and VEGF in cell culture supernatants were measured by enzyme-
linked immunosorbent assay (ELISA) (all purchased from PeproTech, London) 
according to the manufacturer’s instructions. The standard curves for human IL-
8, VEGF, IL-6 and FGF2 ranged from 16-2000 pg/ml, 16-1000 pg/ml, 32-2000 
pg/ml and 63-4000 pg/ml respectively. The individual assays were reported to 
show no cross-reactivity. A summary of an ELISA protocol is outlined here: A 
96-well plate was incubated overnight with the capture antibody at 0.5 µg/ml in 
PBS (pH 7.20 in sterile water), and subsequently blocked with PBS containing 1 
% BSA (R&D Systems). After washing the plate with PBS buffer containing 0.05 
% Tween-20 (R&D Systems), appropriate dilutions of samples and standards 
were added, incubated for 2 hours at room temperature, washed, and incubated 
with a detection antibody for 2 hours at room temperature. After washing, 
streptavidin-HRP conjugate (1:200; R&D Systems) was added. Finally, ABTS 
substrate (100 l) (R&D Systems) was added. The reaction was stopped with 2 
N H2SO4 (R&D Systems), 50 l per well. The plate was read on an ELISA plate-
reader at an optical density (OD) of 450 nm with wavelength correction set at 
650 nm.  
 
2.5.4 Western blotting 
Samples were prepared using RIPA buffer (1 % Nonidet P-40, 0.5 % 
deoxycholate, 0.1 % SDS in PBS) containing a protease inhibitor cocktail 
(Roche), and loading buffer (20 % glycerol, 1M Tris HCl pH 6.8, bromophenol 
blue) to contain an equal amount of protein (20 µg). 15 µl of each sample was 




(Biorad, Hercules, CA, USA). Protein standard markers (Bio-Rad Laboratories) 
were loaded and run parallel to each blot as an indicator of the molecular 
weight. The gels were run in running buffer (25 mM Tris, 192 mM glycine, 1 % 
w/v SDS) at 100 Volts for 1 hour and 20 minutes. The proteins were then 
transferred onto a 0.45 µm nitrocellulose membrane (Sigma-Aldrich, USA) using 
transfer buffer (25 mM Tris, 192 mM glycine) at 30 Volts for 1 hour. After 
transfer, non-specific protein binding was blocked by incubation of the 
membrane with 5% non-fat dry milk in TBS-T buffer (10 mM Tris-HCl, 150 mM 
NaCl, 0.1 % Tween-20) for 1 hour at room temperature. This was followed by 
incubation with primary antibodies: rabbit FGFR1 (1:500; Abgent, Beverly, MA, 
USA) and β-actin (1:2500; Sigma) in milk/TBS-T overnight at 4 °C with rocking. 
The immunoblots were then washed 3 times with TBS-T and incubated with a 
secondary antibody, goat anti-rabbit HRP (1:1000; DakoCytomation) to detect 
binding of the primary antibody for 1 hour at room temperature with gentle 
shaking. The immunoblots were developed and visualised using the Enhanced 
chemiluminescence (ECL) system (Amersham Hyperfilm™ ECL) and a Kodak 
Image station (Kodak Digital Science). When blots for β-actin were not 
performed in parallel to the target, the target blots were stripped using Re-Blot 
Plus Strong Solution (10X; Millipore) and re-probed. 
This protocol was also followed for C3 (1:100; Hycult biotech) and C5 (1:100; 
Hycult biotech) detection. The secondary antibody for both primary antibodies 
was rabbit anti-mouse HRP (1:1000; DakoCytomation). 
 
2.6 Data and statistical analysis 
Results illustrated in the figures were compiled and analysed using Prism. Raw 
data were used for statistical analysis. Immunohistochemical data were 




and paired data, respectively. Paired Student’s t test was used to compare 
treated groups with untreated (control) group. For all tests, P values of less than 













Chapter 3:  Bronchial mucosa 
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3.1 Introduction 
Complement activation has been implicated in the pathogenesis of many 
inflammatory and immunological diseases. Most important biological activities of 
complement are derived from C3 and C5. The split products of C3 are C3a and 
C3b. The breakdown of C3b generates C3d, which binds to antigens and 
enhances their uptake by B cells and dendritic cells. The split products of C5 are 
C5a and C5b. C5b forms the core of the membrane attack complex, or MAC 
(C5b-9). This is the final complex of the complement system, and has multiple 
effects on diverse cells. 
 
Many data suggest a possible role for the anaphylatoxins C3a and C5a in 
asthma and airway remodelling (Baelder et al. 2005). Anaphylatoxins are 
generated in the lungs of both asthmatics and healthy individuals. They are 
classically seen as proinflammatory mediators of allergic asthma that elicit an 
inflammatory response by binding to their respective receptors C3aR and C5aR 
(Lambrecht 2006). Although the expression of C3aR and C5aR on human 
bronchial epithelial and smooth muscle cells has previously been described 
(Drouin et al. 2001b), overall the amount of this expression and cellular 
distribution of these receptors in the human asthmatic bronchial mucosa are 
unknown. There has also not been any specific study to see whether or not 
there is concomitant expression of the anaphylatoxin ligands and their receptors 
in the asthmatic bronchial mucosa. 
 
As seen by most conducted studies and investigations, bronchoscopy and 
bronchial biopsy are the most commonly used techniques for determining the 
extent of airway remodelling (Lazaar & Panettieri 2003). However, there are still 
areas involving asthma and remodelling that are unclear, therefore 
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understanding the pathogenesis and mechanisms driving airway remodelling 
could lead to new approaches to therapy and, specifically, retard the progressive 
decline in lung function that may commence in asthmatics at an early stage 
(Cohen et al. 2007). 
 
 
In view of this it is hypothesised that: 
 
1. Components of complement are expressed in the bronchial mucosa of 
asthmatics; 
2. Bronchial allergen challenge of atopic asthmatics is associated with 
elevated expression of complement components and their receptors in 
the bronchial mucosa; 
3. Assess the number of FGF2 positive cells in the bronchial mucosa of 









3.2.1 Complement staining 
Cells expressing immunoreactivity for the different complement components and 
the two receptors stained brown after developing with DAB (Figure 3.1). 
Omission or substitution of the primary antibody with an isotype matched 
antibody of the same species was used as a negative control. No 
immunoreactivity was observed in the negative controls. Greater detail of the 
staining in individual cell types are shown in Figure 3.2 where expression of C3 
has been used as a representative expression. The bronchial biopsy from an 
asthmatic subject has been used to show an example of how immunoreactivity 
for a particular component was obtained by outlining the individual cells i.e. the 
epithelium. 
 
3.2.2 Complement component immunoreactivity in the bronchial 
mucosa of asthmatics 
Global expression of complement components and their receptors was 
compared in the bronchial mucosa of a group of asthmatics with a range of 
disease severity and normal controls. The characteristics of the patients are 
summarised in Chapter 2, Table 2.1. Comparing all asthmatics with controls 
(Figure 3.3), increased immunoreactivity for C3 and C5b-9 was observed in the 
epithelium, smooth muscle and submucosa, but not the glandular areas of the 
bronchial mucosal sections. C3d immunoreactivity was elevated only in the 
epithelium. Expression of C3a and C5a receptors was detectable on cells in all 
areas of the mucosa (epithelium, submucosa, smooth muscle and glands) 
although the amount of expression did not differ in asthmatics and controls 
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except in the case of the C3aR, expression of which was elevated on smooth 
muscle. 
 
3.2.3 Effect of allergen bronchial challenge of mild atopic 
asthmatics  
Expression of immunoreactivity for the complement fragments and C3a and C5a 
receptors was measured in the bronchial mucosa of mild atopic asthmatics 
before and 24 hours after allergen bronchial challenge. The patients are 
described in Chapter 2, Table 2.1. Changes in expression of all analytes 
measured were not marked following challenge, although C3 immunoreactivity 
was significantly elevated in the bronchial epithelium while C5aR and C3d 
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Figure 3.1 Expression of complement components on asthmatic bronchial tissue by single immunohistochemistry. Sections of bronchial biopsies 




C3 C3d C5b-9 C3aR C5aR





Figure 3.2 Expression of C3 on bronchial tissue by single immunohistochemistry. Purple outline on asthma biopsy shows epithelium. Magnification: 
x40. 
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Figure 3.3 Global expression of immunoreactivity for complement fragments and receptors in sections of the bronchial mucosa from asthmatics 
and controls. Patient characteristics are detailed in Chapter 2, Table 2.1. Figures represent percentages of the total areas of the biopsies stained. Bars show 
mean and SEM for 12 controls and 32 asthmatics. * p<0.05 vs control (Mann-Whitney U test). 
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Figure 3.4 Immunoreactivity for complement fragments and receptors in sections of the bronchial mucosa from mild atopic asthmatics before and 
after allergen challenge. Figures represent percentages of the total areas of the stated sub-structures (epithelium, smooth muscle, submucosa, glandular 
tissue) stained (n=20). * p<0.05 (Wilcoxon matched pairs test). 
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3.2.4 FGF2 staining 
FGF2 immunoreactive cells were measured in sections of bronchial biopsies 
from a group of asthmatics of a range of disease severity and normal controls 
(for details see Chapter 2, Table 2.1). Positive cells stained brown after 
developing with DAB (Figure 3.5). Omission or substitution of the primary 
antibody with an isotype matched antibody of the same species was used as a 
negative control. Cells expressing FGF2 immunoreactivity were observed in 
sections of the bronchial mucosa (total epithelial and submucosal cells) of the 
asthmatics and controls. The positive cells are shown in higher magnification 
(x40) in Figure 3.6 in two bronchial biopsies representative of a normal and an 
asthmatic subject. The median number of FGF2+ cells was higher in the 
asthmatics compared with the controls, a difference largely attributable to 
increased numbers of these cells in the submucosa rather than the epithelium 
(Figure 3.7). FGF2 expression did not correlate with that of any of the 
components of complement or its C3a and C5a receptors (data not shown). 
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Figure 3.5 Expression of FGF2 on asthmatic bronchial tissue by single immunohistochemistry. Sections of bronchial biopsies from normal, mild, 
moderate and severe asthmatic subjects were immunostained for the growth factor FGF2 as described in Chapter 2: Materials & Methods, section 2.2.4. 
Magnification: top panel x20; bottom panel x10.  
 
Normal      Mild     Moderate     Severe 
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normal asthma
 
Figure 3.6 Expression of FGF2+ cells at high magnification on bronchial tissue by immunohistochemistry. FGF2 positive cells shown with arrows. 
Magnification: x40. 













































































Figure 3.7 Numbers of FGF+ cells in the bronchial mucosa, epithelium and submucosa of control and asthmatic subjects. n=10 control subjects, 




The hypotheses set out in this chapter were upheld to some extent although the 
changes observed were very small. Nevertheless, the evaluation of the 
complement components by IHC as presented in this chapter is novel as the 
expression of these particular components has not yet been studied in the 
bronchial mucosa of patients with a range of asthma severity. The most 
important biological activities of complement are derived from C3 and C5 which 
give rise to the anaphylatoxins. The expression of C3a and C5a could not be 
investigated directly in this study because there are no suitable commercially 
available antibodies. Consequently, in addition to the anaphylatoxin receptors 
the expression of C3, C3d and C5b-9 were measured. C3 and C3d were used 
as substitute biomarkers for C3a. C3d, an opsonin, is another smaller cleavage 
product of C3 and it is therefore not unreasonable to hypothesise that its 
production may reflect that of C3a, a larger cleavage product. C5b-9 was 
measured owing to its importance as an end effector following complement 
activation. 
 
Although there are no studies that have investigated the expression of 
complement components in the lungs of subjects with asthma, there is one 
previous study which looked at the expression of the anaphylatoxin receptors in 
lung tissues. Fregonese and colleagues conducted a study on the expression of 
C3aR and C5aR in lung tissue from patients who died of fatal asthma and 
patients who died of nonpulmonary causes (used as controls) (Fregonese et al. 
2005). They showed elevated expression of both receptors in subjects who died 
of asthma compared with control subjects and those with mild intermittent 
asthma (Fregonese et al. 2005). The high expression of C3aR and C5aR shown 
in their study was suggested to be a hallmark of fatal asthma as the intensity of 
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staining of both receptors was noted to be relatively low in biopsies from patients 
with mild intermittent asthma although further, more systematic analysis was not 
pursued. Nevertheless, their data support the hypothesis that complement plays 
an active role in the pathogenesis of fatal asthma and suggest that the airway 
and parenchymal vessels and the airway epithelium might be the major sites of 
action of C3a and C5a during the fatal attacks (Fregonese et al. 2005). 
 
Owing to the limited range of suitable antibodies, the data presented here can 
provide only surrogate evidence for the involvement of complement, particularly 
C3a and C5a in asthma. It is not possible to determine from these data whether 
the immunoreactivity reflects deposition of complement fragments or in situ 
synthesis, or both. 
 
The data provide circumstantial evidence for the involvement of components of 
the complement cascade in the pathogenesis of asthma in the sense that 
increased C3 and C5b-9 immunoreactivity was observed in the epithelium, 
smooth muscle and submucosa, but not the glandular areas of bronchial 
mucosal sections in asthmatic subjects compared with controls. C3d and C3aR 
immunoreactivity were likewise elevated although only in the epithelium and 
smooth muscle respectively. Elevated C5a receptor expression was not 
observed in any area of the bronchial mucosa of the asthmatics compared with 
controls. Although epithelial C3aR expression and submucosal C5aR 
expression correlated inversely with lung function in the asthmatic biopsies, 
these data are difficult to interpret because overall expression of these receptors 
was not elevated in these areas in the asthmatics compared with the controls. 
The data might have been influenced by anti-asthma therapy of the 
moderate/severe asthmatics. Expression of complement fragments and C3a and 
C5a receptors in the bronchial mucosa of mild atopic asthmatics showed little 
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change before and after allergen bronchial challenge. The use of 24-hour post 
allergen challenge could have been late for the expression of the complement 
components to be seen. 
 
Although an obvious pattern of deposition and/or expression was not noted for 
the complement components in the bronchial mucosa, expression of the 
fragments and receptor immunoreactivity was detectable not only in the 
submucosa of the sections, where inflammatory cells such as eosinophils which 
are known to express receptors might have been expected to be situated, but 
also in the epithelium and smooth muscle, supporting the hypothesis that these 
structural cells are at least theoretically capable of responding to stimulation by 
complement fragments. 
 
Our inability to observe elevated FGF2 immunoreactivity in the asthmatic 
biopsies compared with the controls contrasts with a previous report by Shute et 
al in which a more detailed quantitative analysis suggested elevated 
extracellular deposition in the pericellular matrix of both epithelial and 






Chapter 4:  Epithelial Cells
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4.1 Introduction 
The epithelium of the lung represents an immense surface area of interface 
between the environment and the internal milieu, estimated to approximate that 
of a tennis field (Zaas & Schwartz 2005). The epithelial cells lining the airways 
are particularly well adapted to the protection of the airway mucosa from major 
sources of injury (e.g., tobacco smoke, pollutants, viruses, and bacteria) 
(Puchelle et al. 2006). These cells fulfil a number of critical functions in innate 
airway defence mechanisms. At the surface of the airway epithelium (bronchi 
and bronchioles), these specialized cells include columnar ciliated cells, mucous 
(goblet) cells, Clara cells, and basal cells (Puchelle et al. 2006). At the 
submucosal level, the glands form tubules that feed into a collecting duct and 
then into a ciliated duct that is continuous with the airway surface. Tubules are 
lined with mucous cells (proximal region) and serous cells (distal acini). More 
than 90% of the airway mucus is provided by these glands (Puchelle et al. 
2006). These airway cells can rapidly change their structure and functions, 
either to adapt to changes in the local environment or to repair the epithelium 
after injury. In the upper and lower airways, the surface airway epithelium is 
normally pseudostratified (Puchelle et al. 2006). This implies that all cells are 
attached to the basement membrane but not all reach the airway lumen. In the 
proximal bronchioles, the epithelial cells become more cuboidal and, in addition 
to ciliated cells, contain secretory Clara cells. In the most distal bronchioles, only 
Clara cells are identified (Puchelle et al. 2006). 
 
The airway epithelium participates in innate immune responses (Zaas & 
Schwartz 2005). This immune dysregulation is partly responsible for asthma 
pathogenesis, and the airway epithelium has gathered increasing attention as a 
primary driver of asthma (Holgate 2008). Recognition of pathogens is mediated 
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by specific binding of conserved pathogen-associated molecular patterns 
(PAMPs) by pattern-recognition receptors (PRRs). These PRRs are present on 
the surface of leukocytes and airway epithelial cells, and as part of the 
surfactant secreted by the epithelium (Zaas & Schwartz 2005). 
 
A large body of work has focussed on immunological aspects of asthma 
pathogenesis, and the role of a Th2 biased immune response in asthma is well 
supported (McGee & Agrawal 2006). There is evidence that the epithelium of 
asthmatics is fundamentally abnormal, with increased susceptibility to 
environmental injury and impaired repair mechanisms (Kicic et al. 2006). 
Consequently, asthmatic epithelium releases pro-inflammatory mediators as well 
as growth factors that will act on underlying fibroblasts, driving airway 
remodelling (Kicic et al. 2006).  
 
IL-13 is known to be a central mediator of the allergic asthmatic phenotype, 
exerting a number of effects on airway epithelial cells (Wills-Karp 2004). It has 
been shown to play a role in the development of mucous cell hyperplasia 
(Kuperman et al. 2002) and in inducing expression of epithelium-derived growth 
factors (such as TGF-β) and chemokines (such as eotaxin, monocyte 
chemoattractant protein (MCP)-3) to name but a few (Booth et al. 2007). The 
released factors, in turn, affect neighbouring epithelial cells as well as other cell 
types within the airway walls such as fibroblasts and smooth muscle cells as 
well as inflammatory leukocytes (Davies & Holgate 2002). While it is well 
documented that epithelial cells, including those of the airways, produce and 
release growth factors, the mechanism, or mechanisms, regulating cytokine-




There are limited studies exploring complement components in the context of 
the airway epithelium, together with Th2 cytokines and other remodelling 
mediators. Here it was hypothesised that complement components particularly 
the anaphylatoxins are capable of affecting proliferation of airway epithelial cells 
and their production of remodelling mediators. 
 
 
The specific aims of the studies described in this chapter were to:  
 
1. Assess the expression of C3aR and C5aR on lung epithelial cells; 
2. Assess the proliferative response of epithelial cells to stimulation with 
anaphylatoxins and Th2 cytokines; 
3. Examine C3a and C5a-stimulated production of important remodelling 
mediators (growth factors) by epithelial cells at the mRNA and protein 




4.2.1 Expression of complement receptors on lung epithelial cells 
Immunocytochemistry demonstrated that C3aR and C5aR were both expressed 
on airway epithelial cells. Expression of the receptors was detected in the cell 
line A549 (Figure 4.1), in commercially bought primary human bronchial 
epithelial cells (HBEpC) (Figure 4.2) and in primary lung epithelial cells acquired 
by brushing (Figure 4.3). At least in this in vitro culture scenario, virtually 100% 
of epithelial cells from all sources showed evidence of both C3aR and C5aR 
immunoreactivity.  
 
4.2.2 Proliferation of epithelial cells 
Anaphylatoxins and cytokines were examined for their effects on the 
proliferation of primary HBEpC (Figure 4.4). At the concentrations employed, 
both IL-4 and IL-13 induced subtle but significantly elevated proliferation, while 
the combination was synergistic (mean of 160 % of the baseline rate; Figure 
4.4A). Neither TNF-α at the concentration of 10 ng/ml employed nor 2% serum 
(FCS, also present in the anaphylatoxin solutions) exerted any significant effect. 
C3a and C5a also increased proliferation, but with the limited numbers of 
experiments possible this effect was statistically significant only with C3a (Figure 
4.4B and 4.4C). Nanomolar concentrations of the anaphylatoxins were more 
effective than higher concentrations. 





Figure 4.1 Expression of C3aR and C5aR on A549 cells by immunocytochemistry. A549 cells cultured as described in Chapter 2: Materials & Methods, 
section 2.1.1.1 were immunostained for the anaphylatoxin receptors C3aR and C5aR (ICC detailed in Chapter 2: Materials & Methods; section 2.2.5). 
Immunostaining with an isotype matched control primary antibody (IgG1) and omitting the primary antibody (PBS) were used as negative controls. The results 
shown are representative of 3 experiments. Magnification: top panel x10; bottom panel x20. 
 
 
C3aR      C5aR      IgG1      PBS 





Figure 4.2 Expression of C3aR and C5aR on HBEpC by immunocytochemistry. HBEpC cultured as described in Chapter 2: Materials & Methods, section 
2.1.1.3 were immunostained for the anaphylatoxin receptors C3aR and C5aR (ICC detailed in Chapter 2: Materials & Methods; section 2.2.5). 
Immunostaining with an isotype matched control primary antibody (IgG1) and omitting the primary antibody (PBS) were used as negative controls. The results 
shown are representative of 3 experiments. Magnification: top panel x10; bottom panel x20. 
 
 
C3aR      C5aR      IgG1      PBS 




Figure 4.3 Expression of C3aR and C5aR on primary lung epithelial cells (propagated from mucosal brushings) by immunocytochemistry. 
Immunostaining was performed (ICC detailed in Chapter 2: Materials & Methods; section 2.2.5) for the anaphylatoxin receptors C3aR and C5aR. 
Immunostaining with an isotype matched control primary antibody (IgG1) and omitting the primary antibody (PBS) were used as negative controls. The results 
shown are representative of 3 experiments. Magnification: top panel x10; bottom panel x20. 
 
 






















































































































































































Figure 4.4 Effects of inflammatory cytokines, C3a and C5a on proliferation of 
HBEpC. Cells were exposed to conditions for 48 h. Conditions included treatment with 
A) FCS (2%) and inflammatory cytokines (at 10 ng/ml) and their combinations, and B) 
C3a and C) C5a at different concentrations (10-9-10-7 M) (refer to Chapter 2: section 2.3 
for details of proliferation methods). Data are expressed as mean ± SEM of the 
response of 3 independent MTS assay experiments, expressed as a percentage of the 










4.2.3 Complement gene expression in epithelial cells 
The potential of various cytokines to induce expression of genes encoding the 
C3 and C5 complement components and the C3a and C5a anaphylatoxin 
receptors in A549 cells was measured at three time points using qPCR (Figure 
4.5). The concentrations of cytokines employed were 10 ng/ml and 100 ng/ml 
(IFN-γ). Various cytokines both alone and in combination enhanced expression 
of mRNA encoding C3 (Figure 4.5A), C5 (Figure 4.5B), C3aR (Figure 4.5C) and 
C5aR (Figure 4.5D) by A549 cells. The time course of induction varied but in 
general expression of all four analytes was maximal approximately 4 hours of 
stimulation. In terms of expression of C3 and C3aR, IL-4 had the most 
prominent effect at the cytokine concentration employed. The combination of 
TNF-α and IL-1β was also effective. IL-4, IL-13 and IFN-γ were all effective in 
increasing C5 and C5aR mRNA expression. There was evidence of some 
synergy but the experiments were not designed or powered to detect this in fine 
detail.  
 
4.2.4 FGF gene expression in epithelial cells 
The potential of anaphylatoxins and Th2 cytokines to induce the expression of 
pro-fibrotic genes in HBEpC at the mRNA level was assessed by qPCR (Figure 
4.6). Preliminary screening of FGF family genes in these cells (see discussion) 
suggested expression of the following FGFs and their receptors in HBEpC: 
FGF2, FGFR1 and FGFRL1. TNF-α stimulation of HBEpC showed late (24 h) 
downregulation of FGF2 expression and late (24 h) significant upregulation of 
FGFR1 (Figure 4.6A). IL-4 downregulated expression of FGF2 and FGFRL1 
both early (4 h) and late (24 h) following stimulation (Figure 4.6B). The effects of 
IL-13 were similar to those of IL-4 on FGF2 expression and early FGFRL1 
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expression; in addition IL-13 also downregulated FGFR1 mRNA expression at 4 
h (Figure 4.6C). C3a at a concentration of 10-8 M downregulated expression of 
FGF2, FGFR1 and FGFRL1 mRNA early (4 h) after exposure. By the 24 h time 
point expression did not significantly differ from control (Figure 4.6D). C5a at a 
concentration of 10-8 M also reduced expression of FGF2 and FGFR1 mRNA 



































































































































































































Figure 4.5 Effects of cytokines on expression of mRNA encoding complement 
components and receptors in A549 cells by real time qPCR. Cells were treated with 
a range of inflammatory cytokines (at 10 ng/ml and 100 ng/ml (IFN-γ)) for 2, 4 and 8 h to 
measure A) C3 B) C5 C) C3aR D) C5aR mRNA (refer to Chapter 2: section 2.4.3 for 
qPCR materials and methods). Data are expressed as mean ± SEM of the response of 4 
independent experiments normalized relative to 18s mRNA, * p<0.05 increase in 
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Figure 4.6 Relative expression of FGF2, FGFR1 and FGFRL1 mRNA in HBEpC by real time qPCR. Cells were treated with A) TNF-α (10 ng/ml) B) IL-4 
(10 ng/ml) C) IL-13 (10 ng/ml) D) C3a 10-8 M E) C5a 10-8 M for 4 and 24 h (refer to Chapter 2: section 2.4.3 for qPCR materials and methods). Data are 
expressed as mean ± SEM of the response of 3 independent experiments normalized relative to 18s mRNA, * p<0.05 vs control cells at the same time point 
(Student’s t-test). 
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4.2.5 IL-8 and IL-6 protein expression by epithelial cells 
The effects of C3a and C5a on expression of IL-8 by A549 cells were examined 
by ELISA (Figure 4.7). These cells spontaneously produced IL-8. This 
production was somewhat increased by TNF-α used as a positive control but not 
by a range of physiological concentrations of C3a and C5a (Figure 4.7A and B); 
there were no statistical differences observed. Production of IL-6 and TARC by 
the epithelial cell lines A549 and BEAS-2B was also measured by ELISA (refer 
to Chapter 2: Material & Methods; section 2.5.3 for ELISA detail). No production 
of these proteins was detectable to the limits of the assays in the presence of a 
valid standard curve in the presence or absence of C3a and C5a at the same 
concentrations (data not shown). 
 
4.2.6 FGF2 protein expression by epithelial cells 
The effects of C3a, C5a, IL-4, IL-13 and TNF-α on the expression of FGF2 by 
primary HBEpC were studied using ELISA (Figure 4.8). HBEpC spontaneously 
produced considerable amounts of FGF2 in culture which was significantly 
diminished by TNF-α, IL-4, IL-13 and a range of physiological concentrations of 
C3a. The effect of C5a was less clear and did not show a concentration-
response relationship.  
 
4.2.7 Detection of C3a and C5a in epithelial cells 
The effects of proinflammatory and Th2 cytokines (TNF-α, IL-4 and IL-13 at 10 
ng/ml) on the expression of C3a and C5a in A549 cells was examined by 
Western blotting (see Chapter 2: Methods section 2.5.4 for Western blotting 
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details). The cytokines did not induce detectable expression of either 
anaphylatoxin. 
 
4.2.8 Detection of FGFR1 in epithelial cells 
The effects of C3a, C5a and the Th2 cytokines (IL-4 and IL-13 at 10 ng/ml) on 
the expression of FGFR1 in HBEpC was examined by Western blotting (see 
Chapter 2: Methods section 2.5.4 for details). Neither the anaphylatoxins nor the 
cytokines were found to induce detectable expression of this growth factor 



























































































Figure 4.7 Effects of C3a and C5a on IL-8 production in A549 cells. A549 cells were 
stimulated for 24 and 48 h with various concentrations of A) C3a and B) C5a ranging 
from 10-10 M to 10–7 M, and TNF-α at 10 ng/ml as a positive control. Supernatants were 
harvested and IL-8 expression was measured by ELISA (refer to Chapter 2: section 
2.5.3 for details of ELISA method). Data are expressed as the mean ± SEM of 3 
independent experiments. Statistical significance was assessed by Student’s t-test; 






























































Figure 4.8 Effects of inflammatory cytokines, C3a and C5a on FGF2 expression by 
HBEpC. Cells were cultured and stimulated for 48 h with various concentrations of C3a 
and C5a ranging from 10-9 M to 10–7 M and IL-4 and TNF-α at 10 ng/ml. Supernatants 
were harvested and FGF2 expression was assessed by ELISA as described in Chapter 
2: Materials & Methods, section 2.5.3. Data are expressed as mean ± SEM of 3 





The position and location of the airway epithelium makes it an important cell to 
be studied in asthma. The bronchial epithelium is in a key position to translate 
and coordinate inflammatory signals between the luminal space and the lung 
tissue (Hahn et al. 2006). Epithelial cells play important roles in host defence, 
inflammation, and regulation of immune responses (Schleimer et al. 2007).  
 
Epithelial cells act as an initiator, mediator, and regulator in innate and adaptive 
immune responses, as well as the transition from innate immunity to adaptive 
immunity (Wang et al. 2008). Although asthma is an inflammatory disorder of the 
conducting airways involving Th2-type T cells, the epithelium also plays an 
important role in orchestrating the inflammatory response by interacting with 
multiple environmental factors to produce a chronic wound scenario involving 
tissue injury and aberrant repair (Wang et al. 2008). Part of this is a primary 
disruption of epithelial tight junctions that allows inhaled substances to pass 
more easily into the airway wall to interact with immune and inflammatory cells. 
Aberrant communication between the damaged and stressed epithelia leads to 
the generation of growth factors that interact with the underlying mesenchyme to 
promote airway remodelling responses and a more chronic and persistent 
inflammatory phenotype (Wang et al. 2008). Disordered epithelial function with 
reduced antioxidant defence and impaired capacity to produce primary IFN-γ 
may also account for asthmatic susceptibility to air pollution and respiratory virus 
infection, respectively (Holgate 2007). 
 
In this chapter, it has been demonstrated that cell lines such as A549, primary 
lung epithelial cells and mucosal cells outgrown in our own laboratory express 




not a completely new finding; existing studies have used other means to 
demonstrate expression of the receptors and anaphylatoxins such as in situ 
hybridisation (Drouin et al. 2001b) and in vivo studies showing C3a and C5a 
upregulation in the BAL fluid in asthmatic patients (Krug et al. 2001). Drouin and 
colleagues reported positive C3aR and C5aR immunohistochemistry in the 
bronchioles of normal human lung. The signal was localized to the apical 
surface of the bronchial epithelial cells. They also demonstrated positive 
immunohistochemical staining for C3aR and C5aR in cultured human bronchial 
epithelial cells. Furthermore, they established that both receptors are up-
regulated in two distinct murine models of lung inflammation: endotoxaemia and 
OVA-induced asthma (Drouin et al. 2001b). Despite these studies there have in 
contrast been few if any studies of the functional implications of this expression. 
  
In like manner to Th2 cytokines such as IL-4 and IL-13, C3a and C5a increased 
epithelial cell proliferation, although the effect was clearest with C3a. Disordered 
epithelial proliferation is thought to be a fundamental feature of asthma 
pathogenesis, leading to the concept of the EMT unit: the airway epithelium is in 
a key position to regulate the activity of the underlying cell layers and their 
response to external stimuli (Holgate et al. 2000). The importance of epithelial–
mesenchymal interaction is emphasized in the pathophysiological concepts of 
asthma (Holgate et al. 2000), idiopathic pulmonary fibrosis, and other extra-
pulmonary diseases (Hostettler et al. 2008).  Epithelial hyperplasia may be partly 
responsible for the progressive decline in lung function which can be observed 
in some chronic asthmatics; although other processes such as distal airway 
remodelling and air trapping may also contribute (Cohen et al. 2007). It should 
be noted, however, that as with many “remodelling” changes in asthma there is 
very little direct evidence that they impact on lung function. Benayoun and 




that there was a difference in subepithelial basement membrane thickness and 
epithelial integrity in comparison to normal subjects and subjects with mild–
moderate asthma (Benayoun et al. 2003). Vignola and colleagues demonstrated 
in oral corticosteroid-dependent subjects with asthma that there was increased 
epithelial thickness in comparison to subjects with untreated asthma, although 
there was no difference in comparison to normal control subjects (Vignola et al. 
2001). Pepe and associates also demonstrated a non-significant trend to greater 
subepithelial fibrosis in subjects with severe asthma compared with those with 
moderate asthma but found no evidence of epithelial hyperplasia (Pepe et al. 
2005). 
 
The propensity of C3a to induce epithelial proliferation observed in the present 
study may be particularly relevant to the effects of allergen exposure, since 
Ricciardolo and colleagues demonstrated that allergen challenge appears to 
increase epithelial proliferation in subjects with mild asthma (Ricciardolo et al. 
2003). 
 
Multiple cytokines, particularly IL-4, TNF-α and IL-1β increased C3 and C3aR 
mRNA expression in epithelial cells, while IL-4, IL-13 and IFN-γ increased C5 
and C5aR mRNA, underlining the possibility that epithelial cells, particularly in 
an inflammatory environment such as asthma, are potentially capable of 
producing complement components de novo as well as responding to them. This 
extends previous observations, previously only made in immortalised epithelial 
cell lines that various asthma-relevant and other cytokines including IL-4, IL-13, 
TNF-α and IFN-γ can induce C3 production in A549 and BEAS-2B cells 
(Khirwadkar et al. 1993;Zhao et al. 2000;Varsano et al. 2000;Christian-Ritter et 
al. 1994). Khirwadkar and colleagues showed that A549 cells produce multiple 




enhanced C3 production (Khirwadkar et al. 1993). Zhao et al have also shown 
that the proinflammatory cytokines IL-1β, IL-6, TNF-α, and IFN-γ act as potent 
inducers of C3 in A549 cells (Zhao et al. 2000). Similarly, Varsano and 
colleagues showed that BEAS-2B cells spontaneously generate C3, but not C5 
in serum-free media, and that this was enhanced by TNF-α stimulation (Varsano 
et al. 2000). Christian-Ritter and colleagues reported that IL-4 increases C3 
synthesis by A549 cells in a time- and concentration- dependent fashion, and 
maximal increase in C3 synthesis occurred after stimulation of A549 cells with 
IL-4 at 10 ng/ml for 3 days, justifying the use of this cytokine at this 
concentration in the present study (Christian-Ritter et al. 1994). As in the present 
study, the relative abundance of C3 mRNA in A549 cells was found to increase 
following IL-4 treatment, indicating that its effects on C3 production are 
pretranslational (Christian-Ritter et al. 1994).  The new findings in the present 
study suggest that asthma-relevant cytokines may increase the production of C3 
and C5 by primary bronchial epithelial cells as well as their ability to respond to 
derived fragments of these products including C3a and C5a. Thus some of the 
remodelling activities of IL-4 and other cytokines on epithelial cells could 
conceivably be mediated partly through the effects of complement. 
 
Similarly to the remodelling cytokines IL-4 and IL-13, C3a and C5a tended to 
reduce production of mRNA encoding FGF2, FGFR1 and FGFRL1 by primary 
bronchial epithelial cells. These particular growth factors and their receptors 
were singled out for study because preliminary screening of all the FGFs and 
their receptors at the mRNA level showed that only FGF2, FGFR1 and FGFRL1 
mRNA were detectable in the epithelial cells before or after stimulation. Both 
FGFR1 and FGFRL1 (the most recently discovered member of the FGF receptor 
family, also known as FGFR5) are capable of binding all FGF ligands, but 




kinase domain. Both function to control the proliferation, differentiation and 
migration of structural cells in various tissues. The situation is further 
complicated by the fact that some FGFs, including FGF2 can activate receptors 
both intracellularly and extracellularly. The concentration of cytokines used as 
positive controls (generally 10 ng/ml), but 100 ng/ml in the case of IFN-γ were 
chosen because most of the existing literature shows that these particular 
concentrations are optimal for induction of growth factors. 
 
Growth factors such as FGF2 are secreted by epithelial cells. HBEpC 
spontaneously produced high amounts of FGF2 in culture. It is of great interest 
that complement components especially C3a appear to have the capacity to 
reduce the production by epithelial cells of this key growth factor implicated in 
airways remodelling.  The airway epithelium is considered a principal source of 
FGF2 in the airways (Shute et al. 2004). Its elevated expression in asthmatic 
airways has been confirmed by immunohistochemistry in humans (Shute et al. 
2004) and in a nonhuman primate model (Bosse et al. 2006) and inflammatory 
leukocytes including mast cells, macrophages and eosinophils have also been 
reported to produce it (Bosse et al. 2006). Thus complement components could 
in theory inhibit local epithelial production of FGF2 in the asthmatic airway at 
least in some situations. 
 
In contrast to growth and remodelling factors, C3a and C5a did not affect 
production of the chemokine IL-8 by bronchial epithelial cells, while IL-6 
production could not be detected under any of the conditions employed. This 
contrasts with a previous report (Kashyap et al. 2002) which provided precedent 
for the possibility that such effects may be observed and the suggestion that 
C5a stimulates IL-8 production by human bronchial epithelial cells (Kashyap et 




produce IL-6 in asthmatics (Marini et al. 1992). Production of the chemokine 
TARC was also examined based on previous reports that epithelial cells are a 
source of this chemokine (Laberge & El Bassam 2004) and that it is upregulated 
in the BEAS-2B airway epithelial cell line by cytokines including IL-4, IL-13 and 
TNF-α and also in vivo in the asthmatic bronchial mucosa (Sekiya et al. 2000) 
where the expression of TARC immunoreactivity is increased of subjects with 
asthma as compared to normal controls and its expression is prominent in 
epithelial cells (Sekiya et al. 2000). In addition IL-4 and IL-13 alone or in 
combination with TNF-α have been reported to induce the production of eotaxin 
and MCP-4 by bronchial epithelial cells (Matsukura et al. 2001). All of these 
chemokines have been reported to be over expressed in asthmatic airways 
compared with controls in vivo (Sekiya et al. 2000). In addition to being 
chemoattractants for leukocytes, the chemokine TARC may recruit CCR4+ Th2 
T cells which in turn are induced to produce more Th2 cytokines, establishing a 
mechanism for amplifying Th2 responses (Laberge & El Bassam 2004). In our 
hands C5a and C3a at a range of concentrations did not augment IL-8 release 
from A549 cells, while IL-6 and TARC release from A549 and BEAS-2B cells 
could not be detected. These discrepancies might result from the fact that these 
cell lines were immortalised and may have lost functional genes, for example 
those encoding anaphylatoxin receptors or particular cytokines. It is unfortunate 
that primary cell lines were not further examined in this regard. This was 
because this material is much more scarce and preliminary screens with HBEpC 
also failed to detect IL-8 protein production. 
 
In summary, evidence has been presented consistent with the hypothesis that 
anaphylatoxin complement components contribute to airway remodelling by 
altering epithelial cellular proliferation and their production of key remodelling 




pathogenesis, where epithelial remodelling appears to be inherently abnormal. 
Functionally, while complement components could in theory augment epithelial 
proliferation for example following allergen exposure, it appears that they may 

























Chapter 5:  Fibroblast Cells
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5.1 Introduction 
Fibroblasts are the major type of mesenchymal cell present in the matrix of 
connective tissue. Fibroblasts provide structure and function to maintain 
integrity, form and solidarity of lung tissue (Spoelstra, Postma, & Kauffman 
2001). Fibroblasts likely bring about some of the changes associated with 
inflammation and remodelling in asthma and may also recruit and activate 
inflammatory cells. 
 
Airway inflammation develops in airway tissues in response to exposure to 
potentially injurious physical or biological agents. This response includes the 
release of various mediators, among which cytokines and chemokines are 
considered to play major regulatory roles. Fibroblasts, in addition to other tissue 
structural cells, may actively participate in this process by releasing a variety of 
cytokines and chemokines (Takahashi et al. 2006). Fibroblasts are capable of 
responding to a range of mediators, and producing a vast variety of chemokines 
and cytokines upon stimulation, such as IL-8 and TNF-α, which in turn, are able 
to activate inflammatory cells to the lung (Laberge & El Bassam 2004). 
 
Activation of fibroblasts by various mediators alters their phenotype towards a 
transitional mesenchymal fibroblast/smooth muscle phenotype termed a 
myofibroblast. Activation of fibroblasts leads to a shift in fibroblast phenotype 
(Spoelstra, Postma, & Kauffman 2001). Airway remodelling is as a result of a 
change in the fibroblasts in the lung. 
 
Fibroblasts from chronically inflamed tissue differ from fibroblasts obtained from 
normal tissues in cytokine production, pattern of gene expression of matrix 
proteins as well as the rate of cell proliferation (Benayoun et al. 2003). 
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Increased markers of fibroblasts have been reported on the bronchial mucosa of 
asthmatics: accumulation seems to be proportional to disease severity 
(Benayoun et al. 2003). This is thought to be a key feature of remodelling. 
Although in any healing response fibroblasts are attracted to subepithelial 
compartments of mucosal surfaces to effect tissue repair and healing, in asthma 
this appears to become uncontrolled with increased lay down of matrix proteins, 
a phenomenon which is postulated ultimately to result in diminution of lung 
function with time (Crosby & Waters 2010) (Ingram et al. 2011). 
 
Subepithelial fibrosis is a prominent feature of airway remodelling the severity of 
which has been linked, at least in cross-sectional studies, with asthma severity 
(Saito et al. 2003). Subepithelial fibrosis appears to be affected by 
myofibroblasts, which in addition to adding to fibrous protein lay down also have 
contractile properties of their own, thus contributing to the airway narrowing and 
airflow limitation in asthma (Saito et al. 2003). 
 
It is possible that anaphylatoxins are one of the stimuli to drive fibroblast 
proliferation and differentiation in asthma, with consequent effect on mediators, 
such as IL-8 and FGF2 which induce tissue remodelling. 
 
 
The specific aims of the studies described in this chapter were to:  
 
1. Assess the expression of C3aR and C5aR on human lung fibroblasts; 
2. Assess the proliferative response of fibroblast cells to stimulation with 
anaphylatoxins and Th2 cytokines; 
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3. Examine C3a and C5a-stimulated production of important remodelling 
mediators (growth factors) by fibroblasts at the mRNA and protein level, 




5.2.1 Expression of complement receptors on lung fibroblasts 
Immunocytochemistry demonstrated expression of C3aR and C5aR 
immunoreactivity on human pulmonary fibroblast cells (HPFC) (Figure 5.1) 
cultured and stained as described in Chapter 2: Materials & Methods, section 
2.1.2.2. 
 
5.2.2 Proliferation of lung fibroblasts 
Anaphylatoxins and Th2 cytokines were examined for their effects on the 
proliferation of human pulmonary fibroblast cells (Figure 5.2). Of the cytokines, 
TNF-α, IL-4 and IL-13 significantly increased fibroblast proliferation, although IL-
4 was most effective at the particular concentration of 10 ng/ml employed, 
increasing proliferation to a mean of 208.09 ± 7.16 % of baseline (Figure 5.2A). 
IL-4 and IL-13 in combination also induced proliferation although this was similar 
to TNF-α and surprisingly not additive or synergistic. C3a significantly increased 
fibroblast proliferation in the region of 113 % of baseline at a range of 
concentrations embracing the physiological, although in general this effect was 
not as impressive as that of the cytokines and the concentration/response 
relationship was poor owing to inherent variability of the data (Figure 5.2B). C5a 
at the highest concentration employed (10-7 M) induced increased fibroblast 
proliferation (Figure 5.2C). 
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Figure 5.1 Expression of C3aR and C5aR on HPFC by immunocytochemistry. Lung fibroblasts cultured as described in Chapter 2: Materials & Methods, 
section 2.1.2.2 were immunostained for the anaphylatoxin receptors C3aR and C5aR (ICC detailed in Chapter 2: Materials & Methods, section 2.2.5). 
Immunostaining with an isotype matched control primary antibody (IgG1) and omitting the primary antibody (PBS) were used as negative controls. The results 
























































































































































































Figure 5.2 Effects of cytokines, C3a and C5a on proliferation of HPFC. Cells were 
exposed to conditions for 48 h. Conditions include treatment with A) FCS (2%) and 
inflammatory cytokines (at 10 ng/ml) and B) C3a and C) C5a at different concentrations 
(10-9-10-7 M) (refer to Chapter 2: Materials & Methods, section 2.3 for detail on 
proliferation method). Data are expressed as mean ± SEM of the response of 3 
independent MTS assay experiments, expressed as a percentage of the control cells set 




5.2.3 FGF gene expression in lung fibroblasts 
The ability of anaphylatoxins and cytokines to induce expression of FGFs and 
their receptors in primary human lung fibroblasts was measured 4 and 24 hour 
following stimulation by qPCR (Figure 5.3). The particular products analysed 
were defined from a more preliminary screen (see discussion). At the 
concentrations of cytokines employed, TNF-α had little consistent effect on the 
expression of mRNA encoding FGF2, FGF11, FGFR1 and FGFRL1 (Figure 
5.3A). Both IL-4 and IL-13 suppressed fibroblast production of mRNA encoding 
all of these analytes early (4 h) after stimulation, although IL-13 was particularly 
effective in reversing this after 24 hours (Figure 5.3C). C3a at a concentration of 
10-8 M had no significant effect on the expression of mRNA encoding the FGFs, 
while C5a at the same concentration increased expression of mRNA encoding 
FGF11 and FGFR1 and decreased expression of FGF2 (Figure 5.3D and 5.3E). 
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Figure 5.3 Relative expressions of FGF2, FGF11, FGFR1 and FGFRL1 mRNA in HPFC by real time qPCR. Cells were treated with A) TNF-α (10 ng/ml) 
B) IL-4 (10 ng/ml) C) IL-13 (10 ng/ml) D) C3a 10-8 M E) C5a 10-8 M for 4 and 24 h (refer to Chapter 2: section 2.4.3 for qPCR materials and methods). Data 
are expressed as mean ± SEM of the response of 3 independent experiments normalized relative to 18s mRNA, * p<0.05 compared with control cells at the 
same time point (Student’s t-test). 
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5.2.4 IL-6 and IL-8 protein expression by fibroblast cells 
The effects of C3a and C5a on expression and release of IL-6 (Figure 5.4) and 
IL-8 (Figure 5.5) were examined in the human fibroblast cell line MRC-5 by 
ELISA. Robust production of IL-6 and IL-8 (above 700 pg/ml) was observed in 
response to TNF-α used as a positive control. In contrast, neither C3a nor C5a 
at a range of concentrations embracing the physiological significantly altered the 
production of IL-6 or IL-8 by these cells with the exception of C3a at the highest 
concentration tested (10-7 M) which significantly increased IL-6 production. 
Inexplicably, C3a also increased IL-8 production at 10-9 M but there was no 
concentration/response effect. 
 
5.2.5 FGF2 protein expression by fibroblast cells 
The effects of C3a, C5a and cytokines on the expression and release of FGF2 
was studied in HPFC by ELISA (Figure 5.6). Fibroblasts spontaneously released 
FGF2. Production was increased under the conditions employed by IL-4 and 
decreased by IL-13, but TNF-α had no significant effect. Both C3a and C5a at a 
range of concentrations embracing the physiological exerted opposing effects on 
FGF2 production by HPFC: C3a and C5a at the higher concentrations employed 
increased and decreased FGF2 protein expression respectively, whilst C3a and 
C5a at the lower concentrations employed decreased and increased FGF2 
protein expression respectively. 
 
5.2.6 Expression of FGFR1 by fibroblast cells 
The effects of C3a, C5a and cytokines on the expression of FGFR1 by HPFC 
was investigated by Western blotting (Figure 5.7). FGFR1 (92 kDa) was 
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detected in the treated HPFCs showing that HPFC do express FGFR1. However 
a concentration/response effect for the anaphylatoxins was not observed 
following densitometric evaluation, nor did the cytokines have an effect hence 











































































































Figure 5.4 Effects of C3a and C5a on IL-6 production in Fibroblasts. MRC-5 cells 
were cultured as described in Chapter 2: Materials & Methods, section 2.1.2.1 and 
stimulated for 24 and 48 h with various concentrations of A) C3a and B) C5a ranging 
from 10-10 M to 10–7 M, and TNF-α at 10 ng/ml as a positive control. Supernatants were 
harvested and IL-6 expression was measured by ELISA (refer to Chapter 2: section 
2.5.3 for details of ELISA method). Data are expressed as mean ± SEM of the response 
of 3 independent experiments, * p<0.05 compared with medium control at the same time 














































































































Figure 5.5 Effects of C3a and C5a on IL-8 production in Fibroblasts. MRC-5 cells 
were cultured as described in Chapter 2: Materials & Methods, section 2.1.2.1 and 
stimulated for 24 and 48 h with various concentrations of A) C3a and B) C5a ranging 
from 10-10 M to 10–7 M, and TNF-α at 10 ng/ml as a positive control. Supernatants were 
harvested and IL-6 expression was measured by ELISA (refer to Chapter 2: section 
2.5.3 for details of ELISA method). Data are expressed as mean ± SEM of the response 
of 3 independent experiments, * p<0.05 compared with medium control at the same time 



























































Figure 5.6 Effects of inflammatory cytokines, C3a and C5a on FGF2 expression by 
HPFC. Cells were cultured and stimulated for 48 h with various concentrations of C3a 
and C5a ranging from 10-9 M to 10–7 M and Th2 cytokines and TNF-α at 10 ng/ml. 
Supernatants were harvested and FGF2 expression was assessed by ELISA as 
described in Chapter 2: Materials & Methods, section 2.5.3. Data are expressed as 
mean ± SEM of the response of 3 independent experiments, * p<0.05 compared with 












Figure 5.7 Effects of inflammatory cytokines, C3a and C5a on FGFR1 expression 
on HPFC as assessed by Western blot. Cells were stimulated with TNF-α and Th2 
cytokines at 10 ng/ml, and C3a and C5a at two different concentrations (Western 
blotting method detailed in Chapter 2: section 2.5.4). Western blot (of 24 h stimulation) is 




























The data in this chapter clearly demonstrate for the first time that human 
pulmonary fibroblasts express receptors for both anaphylatoxins C3a and C5a. 
In addition, along with IL-4 and IL-13 which are well established “remodelling” 
cytokines, C3a and to a more tentative extent C5a were capable of increasing 
the proliferation of these cells in vitro. Despite little observable effect on FGF2 
mRNA expression both 4 hour and 24 hour after exposure, C3a increased FGF2 
protein secretion by fibroblasts while C5a decreased it. The established 
remodelling cytokines IL-4 and IL-13 clearly decreased the expression by 
fibroblasts of mRNA encoding remodelling mediators such as FGF2 and its 
receptor early after stimulation, but their effects on FGF2 protein secretion were 
less marked, IL-4 producing a slight net increase and IL-13 a slight reduction of 
FGF2 protein secretion. Neither of the anaphylatoxins significantly altered the 
spontaneous production by fibroblasts of IL-6 and IL-8. The precise reasons for 
this apparent discrepancy of the effects of the anaphylatoxins on FGF2 mRNA 
and protein production are not clear but would no doubt be illuminated by a 
more complete understanding of the time course and mechanism of secretion of 
this protein into the exterior. 
 
There is abundant evidence that fibroblasts play a key role in airway 
inflammation and remodelling. The mucosal microenvironment composed of 
structural cells and highly specialised ECM is able to amplify and promote 
inflammation in the airways (Loubaki et al. 2010). In vitro and animal studies 
showed that interactions of inflammatory cells with structural cells play an 
important role in airway inflammation and remodelling (Ramos-Barbon et al. 
2005;Plante et al. 2006). Structural cells, like bronchial fibroblasts, are able to 
produce multiple mediators that can play a role in maintaining and amplifying the 
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inflammatory response in asthma (Loubaki et al. 2010). Numerous studies have 
shown that fibroblasts actively define the structure of tissue microenvironments 
and modulate immune cell behaviour by conditioning the local cellular and 
cytokine microenvironment (Vancheri et al. 2005). Thus, fibroblasts have been 
shown to modulate leukocyte survival and to regulate their differentiation 
(Loubaki et al. 2010). 
  
The demonstration here that anaphylatoxins, particularly C3a can induce 
fibroblast proliferation, a key feature of remodelling, is of great interest since it 
echoes the effects of IL-4 on fibroblasts - which is regarded as a “classic” 
remodelling cytokine. Interestingly TNF-α, chosen as another positive control 
when investigating the effects of anaphylatoxins on fibroblast proliferation, was 
much less effective at the concentration employed, which is surprising in view of 
its powerful regulation of fibroblast effector  activities (Fukuda et al. 2003). 
 
Substantial evidence suggests that IL-13 plays a critical role in the pathogenesis 
of asthma and in fibrotic elements of airway remodelling (Zhou et al. 2007). 
Although IL-13 expression has been reported to be elevated in the lungs of 
patients with asthma, and IL-13 has been proposed to be a major factor in 
asthmatic airway remodelling, evidence that IL-13 alone contributes to the 
airway remodelling and fibrosis in human asthma remains modest (Zhou et al. 
2007). Some studies suggest that in contrast with murine studies, IL-13 alone 
has no effect on collagen expression, while actually increasing MMP production 
(Chen et al. 2005). 
 
The Th2 cytokines are capable of effecting fibroblast proliferation. In the present 
study proliferation of human lung fibroblasts was increased in the presence of 
IL-4 and IL-13 alone, whereas the combination was less effective. The ability of 
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these Th2 cytokines to enhance fibroblast proliferation is consistent with 
previous findings. Kraft et al compared proliferation of fibroblasts from healthy 
controls, mild asthmatics and severe asthmatics, and found that IL-4 and IL-13, 
both alone significantly increased proliferation in the mild asthma group as 
compared with the severe asthma and healthy groups (Kraft et al. 2001). 
Proliferation after exposure to IL-13 was also significantly greater in the mild 
asthma group (Kraft et al. 2001). However, Kraft et al also noted that the 
combination of IL-4 and IL-13 increased fibroblast proliferation significantly in the 
mild asthma group as compared with the severe asthma and healthy groups 
(Kraft et al. 2001). The reason for this discrepancy with the data in the present 
study is not clear but could relate to ex vivo expression of IL-4/IL-13 receptors in 
samples obtained directly from asthmatics. 
  
Saito and colleagues also investigated the effect of IL-4 and IL-13 on the 
differentiation of lung fibroblasts in the presence or absence of the Th1 cytokine 
IFN-γ and found that both IL-4 and IL-13 upregulated proliferation of fibroblasts 
(Saito et al. 2003). Both cytokines induced a morphological differentiation of lung 
fibroblasts to myofibroblasts and upregulated the expression of α-SMA. They 
postulated that IL-4 and IL-13 upregulate fibroblast proliferation largely by 
suppressing the synthesis of PGE2 (Saito et al. 2003). However, other signalling 
pathways induced by IL-4 or IL-13 might participate in cell proliferation (Saito et 
al. 2003). IL-4 and IL-13 can also activate mitogen-activated protein (MAP) 
kinases (Hashimoto et al. 2001) and this pathway can also modulate 
mitogenesis. They also noted that IFN-γ acts on fibroblasts and inhibits 
myofibroblastic differentiation induced by IL-4 and IL-13 (Saito et al. 2003). 
Numerous studies have suggested that IL-4 and IL-13 can act on fibroblasts and 
modulate their inflammatory responses (Hashimoto et al. 2001). It has also been 
previously reported that IFN-γ directly inhibits the production of extracellular 
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matrices by lung fibroblasts (Venkatesan, Roughley, & Ludwig 2002), 
suggesting IFN-γ to be of potential therapeutic benefit for airway remodelling 
(Saito et al. 2003). 
 
A useful extension of the present data for future studies would be to investigate 
possible modulation by anaphylatoxins of surface adhesion and co-stimulatory 
molecules on fibroblasts. Fibroblasts express many surface adhesion and co-
stimulatory molecules related to leukocyte trafficking and signalling such as 
ICAM-1 and VCAM-1 (Bombara et al. 1993). Doucet et al showed that IL-4 and 
IL-13 act on human lung fibroblasts to increase the expression of cell surface β1 
integrin and VCAM-1 adhesion molecules which are implicated in asthma as 
well as in the production of IL-6 and MCP-1, two inflammatory cytokines 
important in the pathogenesis of allergic inflammation (Doucet et al. 1998a). 
Expression of the adhesion molecules ICAM-1 and more particularly VCAM-1 on 
lung fibroblasts may be important for migration of inflammatory cells through the 
submucosa to the airway lumen in the asthmatic inflammatory response 
(Spoelstra et al. 1999). Eosinophil infiltration into the airways, a key feature of 
asthma; is mediated by adhesion of eosinophils to fibroblasts through β2-
integrins and their receptors (e.g. intercellular adhesion molecule-1), but VLA-
4/VCAM-1 interaction could also play a role (Fukuda et al. 1996).  Sabatini and 
colleagues showed that human foetal lung fibroblast cells constitutively 
expressed VCAM-1 and ICAM-1; while both IL-4 and TNF-α increased 
expression of VCAM-1, only TNF-α increased expression of ICAM-1 and 
increased expression of eotaxin and MCP-1 (Sabatini et al. 2002). 
 
It is of great interest that C3a was observed to increase fibroblast production of 
FGF2 only at the protein level, whereas C5a decreased fibroblast production of 
FGF2 both at the protein level and at the mRNA level and increased expression 
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of its receptor FGFR1. The fact that C3a altered FGF2 protein but not early 
mRNA expression suggests that C3a exerts a late effect on FGF2 mRNA 
expression. Although there was no evidence of a concentration/response effect 
for C3a and C5a on FGFR1 expression by western blotting, the data show that 
HPFC do in fact express FGFR1. Existing studies suggest that FGF2 is a critical 
growth factor in fibrosis (Kranenburg et al. 2005). FGF2 has been proposed to 
act as a principal factor inducing fibrogenic and proliferative effects on lung 
fibroblasts (Selige et al. 2010). FGF2 regulates proliferation by interacting with 
its receptor and inducing mitogenesis via the MAP kinases (Thannickal et al. 
1998). Phosphorylation of ERK1/2 has been reported to be important for 
mitogen-mediated proliferation (Khalil et al. 2005). Elevated FGF2 expression is 
a feature of asthma (Barnes 2003); this and other growth factors may act in 
concert with other cytokines such as IL-1β to induce fibrosis in asthma and other 
lung diseases such as Idiopathic pulmonary fibrosis (IPF) (Inoue et al. 2002). In 
addition other growth factors such as TGF-β increase FGF2 production by 
fibroblasts (Khalil et al. 2005). Fibroblasts treated with TGF-β1 show delayed 
(up to 2 hour) FGF2 protein synthesis (Thannickal et al. 1998) whereas it was 
demonstrated by Khalil et al that incubation of fibroblasts with TGF-β1 for as 
little as 1 minute could increase FGF2 release. The rapidity of these effects 
suggests that TGF-β1 induces the release of preformed FGF2. Up to 30 % of 
FGF2 synthesized by a fibroblast may be associated with the surrounding ECM 
(Khalil et al. 2005); these findings therefore suggest that a pool of FGF2 exists 
extracellularly and can be mobilised by growth factors such as TGF-β1 (Khalil et 
al. 2005). FGF2 and FGFR1 expression is upregulated in the remodelled 
airways of mice chronically challenged with allergen (Yum et al. 2011). 
Corticosteroids, on the other hand, reduce expression of both FGF2 and FGFR1 
in the remodelled airway (Yum et al. 2011). FGF2 may influence airway 
remodelling not only through direct mitogenic effects on structural cells such as 
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smooth muscle (Bosse & Rola-Pleszczynski 2008) and fibroblasts (Strutz et al. 
2001), but also through indirect effects on cells such as macrophages, which are 
induced by FGF2 to express the proremodelling cytokine TGF-β1 (Yum et al. 
2011).  
 
Although the anaphylatoxins did not induce IL-6 and IL-8 production by the 
MRC-5 fibroblast cell line, it was possible to confirm abundant production of IL-6 
and IL-8 by these cells in response to the positive control TNF-α stimulus. IL-6 
expression is increased in blood, BAL fluid, and the lung tissues of asthmatic 
patients (Doganci et al. 2005). Moreover, IL-6 derived from antigen-presenting 
cells is able to induce initial IL-4 production in naive CD4+ T cells, thereby 
polarizing these cells into Th2 cells (Loubaki et al. 2010). IL-6 plays an important 
role in asthma tissue remodelling (Loubaki et al. 2010). Multiple lines of 
evidence indicate that IL-6 is a good marker of fibrosis (Loubaki et al. 2010). 
Targeted over-expression of IL-6 in transgenic mice lungs leads to the 
development of sub-epithelial fibrosis (Kuhn et al. 2000). Fibrosis is also 
reduced in IL-6 knockout mice (Natsume et al. 1999). Furthermore, in tissues 
such as the lungs, liver and the skin, IL-6 expression has been shown to 
correlate with fibrosis (Smith et al. 1998;Kayano & Okita 2000;Sato, Hasegawa, 
& Takehara 2001). Loubaki et al showed that the contact between T cells and 
bronchial fibroblasts led to a significant increase in IL-6 production (Loubaki et 
al. 2010). IL-8 is a neutrophilic chemotactic factor that is involved in host 
inflammatory responses and is known to be synthesized by many different cell 
types, including fibroblasts (Amenomori et al. 2010). It attracts neutrophils to 
small airways and lung parenchyma, leading to tissue inflammation and 
destruction. Concordant with the experiments described here, Zhang and 
colleagues demonstrated TNF-α-induced induction of IL-6 and IL-8 in lung 
fibroblasts by ELISA (Zhang, Wu, & Qu 2011).   
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Doucet and colleagues found that human lung fibroblasts derived from either 
foetal or adult tissue as well as from a Th2-type stromal reaction produced IL-6, 
IL-8, IL-11, and MCP-1 as assayed by ELISA, whilst GM-CSF was produced in 
foetal fibroblasts only; eotaxin transcripts were also present in all three types of 
fibroblasts (Doucet et al. 1998a). 
 
In summary, through their effects in increasing fibroblast proliferation and their 
production of key remodelling mediators, anaphylatoxins clearly have a potential 
role to play in remodelling processes in the human asthmatic airways. As with all 
inflammatory processes, there is considerable overlap of these effects with 
those of other mediators, particularly the Th2 cytokines IL-4 and IL-13, although 
evidence has been presented in this chapter that the “fine” functions of all these 
mediators can be distinguished. Further studies are essential to broaden and 












Smooth muscle cells line the airways throughout the entire bronchial tree 
proximal to the terminal bronchioles. In the trachea, parallel bundles of 
trachealis muscle are attached to the cartilage rings. The muscle, found on the 
posterior side of the trachea, is an ideal source for sampling ASM due to the 
neat arrangement of parallel bundles, perpendicular to the long axis of the 
trachea (Amrani, Chen, & Panettieri 2000). Further down the bronchial tree, the 
ASM encircles the airways in a helical manner suggesting that contraction would 
both narrow the airways and shorten their length (Amrani, Chen, & Panettieri 
2000). The airways of asthmatics are known to have an increased mass of ASM. 
Whether this is due to hypertrophy (an increase in size of airway smooth muscle 
cells) or hyperplasia (an increase in the number of airway smooth muscle cells) 
or both is still unclear (Ebina et al. 1993). 
 
In 1922, Huber and Koessler described, for the first time, an increase in ASM 
tissue in the airways of asthmatics (Huber & Koessler 1922). Since then, 
enlargement of peribronchial ASM tissue has become a histopathological 
signature of the disease (Hirst et al. 2004). By generating more force, this 
increased mass of ASM is generally thought to contribute to AHR (Hirst et al. 
2004). 
 
There has been much speculation about the possible physiological function of 
ASM. Human ASM cells are involved in the pathogenesis of asthma, because 
these cells contribute to AHR and airway obstruction (Bloemen et al. 2007). 
ASM is known to proliferate in response to numerous growth factors and 
mediators that are released during allergic airway inflammation both in vitro and 
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in vivo (Gosens et al. 2008). In addition, smooth muscle hypertrophy and 
hyperplasia are accepted features of airways remodelling. 
 
Many inflammatory mediators increased in asthmatic airways induce airway 
smooth muscle proliferation in vitro (Moynihan et al. 2008). Classical mediators, 
such as histamine, thromboxane, and leukotrienes are potent airway smooth 
muscle constrictors and potential smooth muscle mitogens (Moynihan et al. 
2008). Pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α are also 
increased in asthmatic airways and there is some evidence that they enhance 
smooth muscle proliferation. Th2 cytokine receptors, such as IL-4 and 13 
receptors, are also expressed on airway smooth muscle cells (Moynihan et al. 
2008). 
 
An important aspect of interaction between airway inflammation and airway 
smooth muscle is that airway smooth muscle itself could be a source of 
mediators of airway inflammation and remodelling (Moynihan et al. 2008). 
Studies have revealed that airway smooth muscle cells release several 
mediators including cytokines (such as GM-CSF, IL-2, -5, -6, -11, -12, -13, IFN-
γ), chemokines (such as eotaxin, RANTES, IL-8, MCP-1, -2, -3, TARC), growth 
factors (PDGF, IGF, SCF, VEGF) and inflammatory mediators in the airways 
(PGE2, PLA2) (Howarth et al. 2004). Several chemokines are also produced by 
human ASM cells in vitro upon stimulation with cytokines (IL-4, IL-13, IL-1β, 
TNF-α, TGF-β and PAF), including CCL5, CCL7, CCL11, CCL13 and CXCL8 
(Bloemen et al. 2007). For instance, a marked increase in CCL11 
immunoreactivity in ASM was seen in an immunological study of the airways 
from patients with asthma (Black & Johnson 2002). These chemokines are 
involved in the recruitment of inflammatory cells into the lung and promote the 
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upregulation of cell surface adhesion molecules (Bloemen et al. 2007). 
Furthermore GM-CSF, which is an important stimulator of maturation, activation 
and survival of several inflammatory cells, is produced by ASM cells when 
stimulated by a combination of IL-1β and TNF-α (Oltmanns et al. 2003). 
Bradykinin can increase IL-6, CXCL8 and PGE2 release (Pang & Knox 1998). 
Therefore, airway smooth muscle cells might be a source of mediators of airway 
inflammation, and may modulate autocrine proliferative responses (Moynihan et 
al. 2008).  
 
Moynihan and colleagues examined cultured human (H)ASM cells for the 
expression of IL-13 receptor subunits (Moynihan et al. 2008). They found that 
the receptor subunits were expressed on HASM cells, and that pre-treatment 
with IL-4 and IL-13, but not IFN-γ induced desensitization of the HASM cells to 
IL-13 as measured by eotaxin secretion. The mechanism of IL-4 and IL-13 
induced desensitization did not appear to involve downregulation of receptor 
expression (Moynihan et al. 2008). 
 
Animal models demonstrate a role for IL-13 in the development of AHR; 
overexpression of IL-13 in the murine lung induces a phenotype similar to 
human asthma, with excess mucus production, goblet cell hyperplasia and 
smooth muscle hypertrophy (Zhu et al. 1999). IL-13 and IL-4/IL-13 knockout 
mice are protected from allergen induced AHR (Leigh et al. 2004). Interferon-γ 
may counteract the actions of IL-4 and IL-13 in some circumstances. IFN-γ 
knockout mice have been shown to have augmented Th2 responses and IFN-γ 
knockout mice have enhanced AHR following allergen challenge that is restored 
by administration of recombinant IFN-γ (Yoshida et al. 2002). 
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Although there are many studies on airway smooth muscle cells and their role in 
asthma, there are few in the context of the complement system together with 
Th2 cytokines and growth factors. Here it was hypothesised that complement 
components, particularly the anaphylatoxins are capable of increasing 
proliferation of human airway smooth muscle cells and their production of 
remodelling mediators.  
 
 
The specific aims of the studies described in this chapter were to: 
 
1. Assess the expression of C3aR and C5aR on human smooth muscle 
cells; 
2. Assess the proliferative response of smooth muscle cells to stimulation 
with anaphylatoxins and Th2 cytokines; 
3. Examine C3a and C5a-stimulated production of important remodelling 
mediators (such as growth factors) by smooth muscle cells at the mRNA 
and protein level, comparing with Th2-type cytokine-stimulated 
production as a positive control. 
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6.2 Results 
6.2.1 Expression of complement receptors on primary cultured 
human airway smooth muscle cells 
Examination of these cells by light microscopy revealed an elongated, linear and 
spindle shaped morphology with prominent nuclei usually in the centre. 
Immunohistochemistry demonstrated that C3aR and C5aR were both expressed 
on airway human smooth muscle cells (Figure 6.1). This pattern of staining was 
observed consistently in all smooth muscle cell cultures that were stained in this 
fashion. 
 
6.2.2 Proliferation of airway smooth muscle cells 
The effect of the anaphylatoxins and inflammatory cytokines on the proliferation 
of human smooth muscle cells (HSMC) was studied. IL-4 induced statistically 
significant proliferation, whereas IL-13 alone did not. However, the combination 
further induced proliferation to a mean of 135.37 % of the baseline rate (Figure 
6.2A). C3a at a relatively high concentration of 10-7 M also significantly 
increased proliferation (Figure 6.2B) but not at lower concentrations. C5a in the 
concentration range of 10-9-10-7 M exerted no significant effect (Figure 6.2C). 
The concentration-response curves were blunted by the inherent variability of 
individual responses. 
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C3aR      C5aR      IgG1      PBS 
Figure 6.1 Expression of C3aR and C5aR on HSMC by immunocytochemistry. HSMC cultured as described in Chapter 2: Materials & Methods, section 
2.1.3.1 were immunostained for the anaphylatoxin receptors C3aR and C5aR (ICC detailed in Chapter 2: Materials & Methods, section 2.2.5). Immunostaining 
with an isotype matched control primary antibody (IgG1) and omitting the primary antibody (PBS) were used as negative controls. The results shown are 





































































































































































































Figure 6.2 Effects of cytokines, C3a and C5a on proliferation of HSMC. Cells were 
exposed to conditions for 48 h. Conditions included treatment with A) FCS (2%) and 
inflammatory cytokines (at 10 ng/ml) and B) C3a and C) C5a at different concentrations 
(10-9-10-7 M) (refer to Chapter 2: section 2.3 for details of proliferation method). Data are 
expressed as mean ± SEM of the response of 3 independent MTS assay experiments, 
expressed as a percentage of the control cells set to 100%. * p<0.05 for induction of 
proliferation vs control (Student’s t-test). 
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6.2.3 FGF gene expression in airway smooth muscle cells 
Cultured HSMC were screened for the expression of FGF ligands and receptors 
at the mRNA level (Figure 6.3). The particular products analysed were defined 
from a more preliminary screen. Gene expression of FGF2, FGF17 and FGFR4 
in HSMC was measured at 4 and 24 hours following stimulation and analysed by 
qPCR.  TNF-α stimulation of HSMC at the concentrations employed had no 
significant effect on the expression of mRNA encoding the FGF ligands and 
receptor (Figure 6.3A). IL-4-stimulated HSMC showed an early (4 h) 
upregulation in the expression of mRNA encoding FGF17, which was 
downregulated at 24 hours compared to control (Figure 6.3B). Similarly, IL-13 
stimulation showed a late (24 h) downregulatory response in the expression of 
FGF17 mRNA; there was a trend for earlier upregulation, which was not 
significant because of large variation between the samples (Figure 6.3C). Both 
Th2 cytokines had no effect on FGF2 and FGFR4 expression at the mRNA 
level. C3a considerably reduced expression of mRNA encoding FGF2 both early 
and late after stimulation; mRNA encoding FGF17 showed late suppression by 
C3a (Figure 6.3D). A similar late response was observed with C5a, which 
reduced HSMC expression of mRNA encoding FGF2 and FGF17 to 50 % or 
less of the basal level (Figure 6.3E). 
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Figure 6.3 Gene expression (relative to control cultures) encoding FGF2, FGF17 and FGFR4 mRNA in HSMC by real time qPCR. Cells were treated 
with A) TNF-α (10 ng/ml) B) IL-4 (10 ng/ml) C) IL-13 (10 ng/ml) D) C3a 10-8 M E) C5a 10-8 M for 4 and 24 h to measure FGF mRNA levels (qPCR detailed in 
Chapter 2: Materials & Methods, section 2.4.3). Data are expressed as mean ± SEM of the response of 3 independent experiments normalized relative to 18s 
mRNA. Statistical significance was assessed by Student’s t-test, * p<0.05 vs. control cells at the same time point. 
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6.2.4 FGF2 protein expression by smooth muscle cells 
The effects of C3a, C5a and cytokines (at 10 ng/ml) on the expression and 
release of FGF2 were studied in HSMC by ELISA (Figure 6.4). HSMC 
spontaneously released FGF2. However, production was suppressed to around 
half of the basal level under the conditions employed by TNF-α, IL-4, IL-13 as 
well as the anaphylatoxins. Both C3a and C5a inhibited FGF2 production at all 
physiological concentrations.  
 
6.2.5 Detection of FGFR1 in smooth muscle cells 
The effects of C3a, C5a and the Th2 cytokines (IL-4 and IL-13 at 10 ng/ml) on 
the expression of FGFR1 was investigated by Western blotting (see Chapter 2: 
section 2.5.4 for western blotting method). Neither the anaphylatoxins nor the 
cytokines were found to induce detectable expression of this growth factor 

























































Figure 6.4 Effects of inflammatory cytokines, C3a and C5a on FGF2 expression by 
HSMC. Cells were cultured and stimulated for 48 h with various concentrations of C3a 
and C5a ranging from 10-9 M to 10–7 M and Th2 cytokines and TNF-α at 10 ng/ml. 
Supernatants were harvested and FGF2 expression was assessed by ELISA as 
described in Chapter 2: Materials & Methods, section 2.5.3. Data are expressed as 
mean ± SEM of the response of 3 independent experiments, * p<0.05 compared with 






In this chapter it has been shown that primary cultured human airway smooth 
muscle cells express anaphylatoxin receptors, and that complement 
components have the propensity to regulate smooth muscle cellular proliferation 
and the production of key remodelling mediators. 
 
ASM proliferation is of functional relevance in asthma because smooth muscle 
hyperplasia is thought to be a fundamental feature of airway remodelling and 
asthma pathogenesis (Takeda et al. 2006). A study by Lambert and colleagues 
suggested that if airway smooth muscle contractile properties are maintained, 
increased airway smooth muscle mass in asthma may be the single most 
important contributing factor to exaggerated airway narrowing (Lambert et al. 
1993). Thus it is critical to elucidate the factors that may modify the proliferation 
of human airway smooth muscle cells.   
 
Nevertheless it is somewhat controversial whether smooth muscle proliferation 
does in fact occur in human asthma (Benayoun et al. 2003;Woodruff et al. 
2004). An ex vivo assessment of proliferative markers showed no evidence of 
increased basal proliferation of myofibroblasts cultured from asthmatic biopsies 
(Ward et al. 2008). Immunostaining for cyclin D1, a marker of proliferation, 
revealed that although cyclin D1 immunoreactive cells increased with asthma 
severity, with a 3.5-fold higher median value for severe asthmatics compared 
with non-asthmatics (Ward et al. 2008), cyclin D1 immunoreactivity was not 
detected in the smooth muscle bundles but was restricted to the epithelium and 
subepithelial connective tissue areas of the histological sections (Ward et al. 




related changes in proliferation may be less apparent when cells are maintained 
in culture isolated from the asthmatic micro-environment of the intact airway 
wall.  On the other hand there are reports of enhanced spontaneous proliferation 
of human ASM cells from asthmatics compared with controls (Black & Johnson 
2002). 
 
IL-4 and IL-13 have previously been shown to affect ASM proliferation either 
directly or by altering ASM responsiveness to other mitogens (Hawker et al. 
1998;Hirst et al. 2004;Faffe et al. 2006). In our hands and, albeit at a single 
physiological concentration, IL-4 but not IL-13 alone increased smooth muscle 
proliferation, but they showed an impressive effect in combination. Bosse and 
colleagues reported a similar effect of IL-4 and IL-13 on ASM cell proliferation, 
supporting a potential role for both cytokines in airway remodelling (Bosse et al. 
2008). Other studies have on the other hand suggested that IL-4 suppresses 
proliferation of ASM cells (Faffe et al. 2006). 
 
IL-4Rα as well as IL-13RαI and IL-13RαII have all been reported to be 
constitutively expressed in human ASM cells (Tomlinson, Wilson, & Stewart 
1994). However, there are limited data on the signalling pathway of IL-4 after it 
binds to its receptor (Hirst et al. 2004). In one study on cultured human ASM 
cells, both IL-4 and IL-13 activated IL-4Rα and induced phosphorylation of its 
signal transducer and activation of transcription-6 (STAT6), p42/p44 ERK and 
p38 MAP kinase (Tomlinson, Wilson, & Stewart 1994). However, since ERK and 
p38 MAP kinase are known to be important intracellular pathways for cell 
proliferation, it is unlikely that IL-4 suppresses ASM cell proliferation through 
them (Hirst et al. 2004). It has been suggested that IL-4 decreases ASM cell 
proliferation by decreasing cyclin D1 protein expression rather than a c-AMP 





IL-13 has diverse effects on HASM cells that may have important implications 
for the pathobiology of asthma (Moynihan et al. 2008). However the responses 
of HASM cells to the presence of IL-13 is likely to be conditioned by the 
prevalent cytokine milieu (Moynihan et al. 2008). Exposure of HASM cells to 
IFN-γ reduced the effects of IL-13 on STAT6 activation but did not appear to 
have much effect on calcium responses to histamine and on eotaxin secretion, 
which are important measures of contractile and secretory properties of HASM 
(Moynihan et al. 2008). 
 
The new data reported in this study suggest that C3a, at high physiological 
concentrations, but not C5a can alter smooth muscle proliferation. Thus the 
anaphylatoxins must be added to the list of mediators potentially able to 
influence HASM proliferation. 
 
FGF2 features highly in the remodelling literature. It is the only member of the 
FGF family known to be upregulated in asthma and has been reported to 
increase ASM proliferation alone or in synergy with IL-4/IL-13 (Bosse et al. 
2008). The new data in the present study suggest that C3a and C5a might 
antagonise this. In our study the same concentrations of IL-4 and IL-13 (both at 
10 ng/ml) were used as in Bosse et al’s study. In contrast to the present 
findings, Bosse et al did not find that IL-4 at the same concentration as in the 
present study increased BSMC proliferation, but the IL-13 finding was in 
accordance in the sense that IL-13, at different concentrations, including at 10 
ng/ml, did not affect BSMC proliferation when administered alone but altered the 
effects of other cytokines (Bosse et al. 2008). On the other hand a study by 
Hawker and colleagues suggested that IL-4 reduced the mitogenic effect of 




to either promote or inhibit airway smooth muscle proliferation in vitro. The 
conflicting results could partly reflect the methods employed to measure cellular 
proliferation. TNF-α also has a small stimulatory effect on human airway smooth 
muscle proliferation (Hawker et al. 1998). In addition, TNF-α, like IL-4, can 
inhibit mitogen-induced proliferation of human airway smooth muscle cells 
(Stewart et al. 1995). In our hands TNF-α had no significant effect on the growth 
factors tested. The data might have been clearer had the numbers of 
experiments been increased. 
 
FGF2 has also been reported to enhance the proliferative effect of TGF-β on 
ASM (Bosse et al. 2006) so C3a may also influence this effect. TGF-β, known 
as a growth factor inducing cell differentiation and fibrosis, is well known to be 
over-expressed in asthma. In addition, eosinophils, a major player in allergic 
airway inflammation, appear to be a major source of TGF-β (Ohno et al. 1996). 
 
Preliminary screening of the FGFs and their receptors at the mRNA level 
showed that only FGF2, FGF17 and FGFR4 appeared to be regulated by 
anaphylatoxin and Th2 cytokines in airway smooth muscle cells. C3a and C5a 
reduced FGF2 and FGF17 expression at the mRNA level and FGF2 at the 
protein level. This suggests that C3a and C5a may be able to inhibit 
remodelling. Inhibition of FGF17 by C3a and C5a might be important as this 
growth factor is fairly new in the context of asthma and remodelling. FGF17 is a 
molecule analogous to FGF8 (which was originally isolated as an androgen-
induced growth factor (AIGF)) and has been found in the smooth muscle of 
major artery walls. Both FGF2 and FGF17 are capable of binding FGFR4. The 
precise repertoire of FGF receptors on human ASM is not well defined but could 
include FGFR1c. FGF2 seems to possess a greater binding specificity for the 




activity toward the FGFR1b-splice form (Ornitz et al. 1996). This is unlike FGF1, 
which appears to be a universal FGFR ligand. Kranenburg and coworkers have 
detected FGFR1 in vascular smooth-muscle cells, ASM cells and the airway 
epithelium (Kranenburg et al. 2002). It is thus believed that the FGFR1c is 
expressed on ASM cells and might be responsible for the FGF2-mediated 
biological effects.  
 
Collectively, the published studies regarding the expression of FGF2 and its 
receptor in asthmatic airways consistently reported an increased expression of 
FGF2, although the cellular origin of this FGF2 and the precise receptor(s) 
responsible for transducing its biological effects in ASM remain to be clarified 
(Bosse & Rola-Pleszczynski 2008).  
 
By upregulating (at least modestly in the case of C3a) ASM proliferation and 
suppressing FGF2 production anaphylatoxins could be contributing significantly 
to the functional activities of these mediators in remodelling. The research 
outlined in this chapter suggests that anaphylatoxins, their receptors, as well as 
Th2 and other cytokines may exert direct effects and have an impact on smooth 








Chapter 7:  Endothelial Cells
 162 
7.1 Introduction 
Common to all vessels of the vasculature is the endothelium, which is a single 
layered sheet of squamous, polarised cells that are primarily responsible for all 
signalling and transportation from blood to tissue and vice versa (Cines et al. 
1998). The endothelium plays an important role in inflammation by actively 
participating in its initiation and propagation (Albrecht et al. 2004). 
 
Activation of the endothelium by lipopolysaccharide (LPS) or TNF-α is known to 
promote the expression of adhesion proteins (eg, E-selectin, ICAM-1, VCAM-1) 
that initiate adhesive interactions with blood leukocytes (Albrecht et al. 2004). 
These adhesive interactions may cause leukocytes to encounter chemokines on 
the endothelial surface, which results in leukocyte activation and engagement of 
leukocyte integrins (LFA-1 and Mac-1, VLA-4) with their counter receptors 
(ICAM-1 and VCAM-1) on endothelial cells (Albrecht et al. 2004). The resulting 
firm attachments enable leukocytes to move through endothelial junctions. Thus, 
physical interactions between the endothelium and leukocytes are part of the 
inflammatory response, whereas additional contributions are provided by 
leukocytic receptors, which ligate inflammatory mediators such as C5a, TNF-α, 
and CXC chemokines (Albrecht et al. 2004). 
 
Endothelial cells are important in angiogenesis and neovascularisation, key 
processes in remodelling in asthma and many other pathological processes e.g. 
tumour metastasis. As the body ages, so does the vasculature and ageing of the 
vasculature is accompanied by a number of changes such as reduced 
vasoregulation, delayed and/or altered angiogenesis, reduced repair capacity 





Different types of endothelial cells have been isolated and cultured to 
understand the biology and pathobiology of the vasculature and the angiogenic 
response. The most widely used type isolated from human umbilical vein 
(named HUVEC) shows a characteristic cobblestone shape when cultured, 
although cell borders are indistinct and hard to visualize (Jaffe et al. 1973). In 
addition to HUVEC, primary cultures of human pulmonary microvascular 
endothelial cells (HPMEC) isolated from single normal human donors were also 
studied. 
 
Very few studies have been performed on endothelial cells in the context of 
asthma and the complement system. It was hypothesised that C3a and C5a play 
a role in effecting airway remodelling by acting on endothelial cells to induce 
remodelling changes or production of remodelling mediators.  
 
 
The specific aims of the studies described in this chapter were to: 
 
1. Assess the expression of C3aR and C5aR on endothelial cells; 
2. Assess the proliferative response of endothelial cells to stimulation with 
anaphylatoxins and Th2 cytokines;  
3. Examine C3a and C5a-stimulated production of IL-6 and IL-8 by 
endothelial cells at the mRNA and protein level, comparing with Th2-type 





7.2.1 Expression of complement receptors on endothelial cells 
Immunocytochemistry demonstrated that both HUVEC (Figure 7.1) and HPMEC 
(Figure 7.2) expressed both C3aR and C5aR. 
 
7.2.2 Proliferation of endothelial cells 
Effects of anaphylatoxins and cytokines on endothelial cellular proliferation were 
studied. While both IL-4 and IL-13 at 10 ng/ml did not induce significant HPMEC 
proliferation alone, the combination of both did (Figure 7.3A). TNF-α at this 
single concentration was similarly ineffective.  FCS (2%), present in the 
anaphylatoxin solutions, also increased HPMEC proliferation. C3a at a range of 
physiological concentrations significantly induced increased proliferation 
although there was little evidence of a concentration response effect (Figure 
7.3B). In contrast, C5a did not have any significant effect on the proliferation of 
HPMEC (Figure 7.3C), although the considerable between experiment variability 








Figure 7.1 Expression of C3aR and C5aR on HUVEC by immunocytochemistry. HUVEC cultured as described in Chapter 2: Materials & Methods, 
section 2.1.4.1 were immunostained for the anaphylatoxin receptors C3aR and C5aR (ICC detailed in chapter 2: Methods; section 2.2.5). Immunostaining 
with an isotype matched control primary antibody (IgG1) and omitting the primary antibody (PBS) were used as negative controls. The results shown are 
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Figure 7.2 Expression of C3aR and C5aR on HPMEC by immunocytochemistry. HPMEC cultured as described in Chapter 2: Materials & Methods, 
section 2.1.4.2 were immunostained for the anaphylatoxin receptors C3aR and C5aR (ICC detailed in chapter 2: Methods; section 2.2.5). Immunostaining 
with an isotype matched control primary antibody (IgG1) and omitting the primary antibody (PBS) were used as negative controls. The results shown are 
representative of 3 experiments. Magnification: top panel x10; bottom panel x20. 
 
 






























































































































































































Figure 7.3 Effects of inflammatory cytokines, C3a and C5a on proliferation of 
HPMEC. Cells were exposed to conditions for 48 h. Conditions included treatment with 
A) FCS (2%) and inflammatory cytokines (at 10 ng/ml) and B) C3a and C) C5a at 
different concentrations (10-9-10-7 M) (refer to Chapter 2: section 2.3 for details of 
proliferation method). Data are expressed as mean ± SEM of the response of 3 
independent MTS assay experiments, expressed as a percentage of the control cells set 






7.2.3 FGF gene expression in endothelial cells 
The potential of anaphylatoxins and Th2 cytokines to induce the expression of 
pro-fibrotic genes in endothelial cells at the mRNA level was assessed by qPCR 
(Figure 7.4). The particular growth factors analysed were defined from a more 
preliminary screen (see discussion). Expression of mRNA encoding FGF2, 
FGFR1, FGFR4 and FGFRL1 in HPMEC were measured at 4 and 24 hour 
following stimulation. Both IL-4 and IL-13 upregulated expression of mRNA 
encoding FGF2 and FGFR4 early (4 h) after stimulation, with both early and late 
(24 h) significant downregulation of mRNA encoding FGFRL1. Both cytokines 
also upregulated expression of mRNA encoding FGF2 late (24 h) after 
stimulation. In addition, IL-13 significantly upregulated FGFR1 mRNA 
expression late (24 h) after stimulation. TNF-α did not alter expression of any of 
these mRNA species in the endothelial cells. C3a at a concentration of 10-8 M 
upregulated FGF2 mRNA early (4 h) after exposure. There was a trend for an 
effect of C5a particularly on FGF2 and FGFR4 upregulation but the variability of 
the data precluded statistical significance.  
 
7.2.4 IL-6 and IL-8 protein expression by endothelial cells 
The effects of C3a and C5a on the expression of IL-6 (Figure 7.5) and IL-8 
(Figure 7.6) were examined in HUVEC by ELISA. HUVEC spontaneously 
produced low amounts of IL-6 in culture which was greatly augmented by TNF-α 
(used as a positive control: Figure 7.5). Spontaneous production of IL-8 by 
HUVEC was higher still and still clearly augmented by TNF-α (Figure 7.6). By 
comparison, C3a had no significant effect on IL-6 or IL-8 production at a range 




employed slightly increased IL-6 (at 10-10 M) and IL-8 (at 10-10 M to 10–9  M) 
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Figure 7.4 Relative expressions of FGF2, FGFR1, FGFR4 and FGFRL1 mRNA in HPMEC by real time qPCR. Cells were treated with A) TNF-α (10 
ng/ml) B) IL-4 (10 ng/ml) C) IL-13 (10 ng/ml) D) C3a 10-8 M E) C5a 10-8 M for 4 and 24 h to measure FGF mRNA levels (qPCR method detailed in Chapter 2: 
Materials & Methods, section 2.4.3). Data are expressed as mean ± SEM of the response of 3 independent experiments normalized relative to 18s mRNA. 








































































































Figure 7.5 Effects of C3a and C5a on IL-6 production in HUVEC. Cells were cultured 
as described in Chapter 2: Materials & Methods, section 2.1.4.1 and stimulated for 24-72 
h with various concentrations of A) C3a and B) C5a ranging from 10-10 M to 10–7 M, and 
TNF-α at 10 ng/ml as a positive control. Supernatants were harvested and IL-6 
expression was measured by ELISA (refer to Chapter 2: Materials & Methods, section 
2.5.3 for details of ELISA method). Data are expressed as the mean ± SEM of 3 









































































































Figure 7.6 Effects of C3a and C5a on IL-8 production in HUVEC. Cells were cultured 
as described in Chapter 2: Materials & Methods, section 2.1.4.1 and stimulated for 24-72 
h with various concentrations of A) C3a and B) C5a ranging from 10-10 M to 10–7 M, and 
TNF-α at 10 ng/ml as a positive control. Supernatants were harvested and IL-8 
expression was measured by ELISA (refer to Chapter 2: Materials & Methods, section 
2.5.3 for details of ELISA method). Data are expressed as the mean ± SEM of 3 





7.2.5 FGF2 protein expression by endothelial cells 
The effects of C3a, C5a, the Th2 cytokines IL-4 and IL-13 and the 
proinflammatory cytokine TNF-α on the expression of FGF2 by HPMEC was 
studied using ELISA (Figure 7.7). HPMEC spontaneously produced FGF2 in 
culture, and all of these mediators inhibited the production of FGF2 by HPMEC 
under the conditions employed. 
 
7.2.6 Detection of FGFR1 in endothelial cells 
The effects of C3a, C5a and the Th2 cytokines (IL-4 and IL-13 at 10 ng/ml) on 
the expression of FGFR1 in HUVEC was investigated by western blotting (see 
Chapter 2: section 2.5.4 for western blotting method). Neither the 
anaphylatoxins nor the cytokines were found to induce detectable expression of 
this growth factor receptor (data not shown). 
 
7.2.7 VEGF protein expression by endothelial cells 
The effects of C3a and C5a on the expression of VEGF in HUVEC were 
examined by ELISA. The anaphylatoxins were unable to induce detectable 






























































Figure 7.7 Effects of inflammatory cytokines, C3a and C5a on FGF2 expression by 
HPMEC. Cells were cultured and stimulated for 48 h with various concentrations of C3a 
and C5a ranging from 10-9 M to 10–7 M and Th2 cytokines and TNF-α at 10 ng/ml. 
Supernatants were harvested and FGF2 expression was assessed by ELISA as 
described in Chapter 2: Materials & Methods, section 2.5.3. Data are expressed as 






In this chapter are presented investigations into possible effects of Th2 
remodelling cytokines and anaphylatoxins on endothelial cells which may be 
relevant to remodelling processes in asthma. 
 
It was confirmed that the complement receptors C3aR and C5aR are expressed 
on endothelial cells of pulmonary and umbilical vein origin. The expression of 
C3a and C5a receptors on HUVEC has previously been reported and this 
observation has been confirmed and extended here to include HPMEC 
(Monsinjon et al. 2003). The presence of these receptors indicates the potential 
for endothelial cells to respond to anaphylatoxins. 
 
HUVECs are the most extensively studied type of endothelial cell, primarily 
because they are relatively easy to isolate and culture. Somatic microvascular 
endothelial cell types, which have recently become available, are not thoroughly 
characterised, although they are interesting from a physiological point of view 
(Boisen et al. 2010). Morphologically, HUVEC and HPMEC cultures are quite 
similar with slight variations in shape from the traditional cobblestone 
appearance to more of a spindle shape, although the degree of confluence in 
the cultures can influence the cell shape (Boisen et al. 2010). On the other hand 
HUVEC appear to senesce more rapidly than HPMEC in vitro, so the former 
have to be used early, typically after 2-3 passages in vitro following isolation, 
whereas HPMEC grow more slowly and require more passages in vitro to raise 
sufficient cell numbers. 
 
In this study HPMEC were used for proliferation and growth factor production 




because Monsinjon and colleagues found anaphylatoxins to increase their 
production and we wanted to replicate this before using primary cells. There is 
some evidence that endothelial cell properties vary according to their site of 
origin (Burg et al. 2002) or even the size of the vessels from which they are 
derived (Meyrick, Christman, & Jesmok 1991). It would have been more 
satisfactory, therefore, to have used HPMEC throughout or at least compared 
these with HUVEC in each of the functional experiments. 
 
The literature indicates that, of the fibroblast growth factors, FGF2 seems to be 
most highly expressed in the vascular compartments of the lung (Powell et al. 
1998;Marek et al. 2009). FGF2 is an extremely important stimulator of 
angiogenesis, endothelial cell growth and the remodelling of ECM proteins 
through which new vessels grow (Desouza, Gerety, & Hamel 2009). 
Correspondingly, the remodelling cytokines IL-4 and IL-13 upregulated FGF2 
mRNA expression early after stimulation of endothelial cells but this was 
accompanied by reduced release of FGF2 protein. Although mRNA encoding 
FGFR1, the FGF2 receptor was detectable in these cells it was not possible to 
detect expression of the immunoreactive protein. C3a and C5a did not 
significantly alter the production of mRNA encoding FGF2 and FGFR1, although 
there was a trend for an increase, but as with IL-4 and IL-13 production of FGF2 
protein was actually reduced. The reason for this paradox is not clear.  
 
It is intriguing that both C3a and C5a along with IL-4 and IL-13 appeared to 
reduce spontaneous FGF2 protein production by endothelial cells in vitro. This 
suggests the possibility that C3a and C5a may actually reduce angiogenesis 





VEGF is also an important remodelling factor influencing endothelial cell growth. 
VEGF and FGF are among the most important growth factors for endothelial 
cells (Desouza, Gerety, & Hamel 2009). VEGF is a powerful mitogen for 
endothelial cells and has been shown to accelerate endothelial regrowth and 
attenuate intimal hyperplasia post angioplasty (Ferrara 2005). In the present 
study the anaphylatoxins were unable to induce detectable VEGF protein 
production by HUVEC measured by ELISA. 
 
C5a, at least at low nanomolar concentrations, but not C3a increased IL-8, but 
not IL-6 production by HUVEC. These data differ from those of Monsinjon and 
colleagues who reported that both C3a and C5a stimulation of these cells 
increased their expression of IL-8 (Monsinjon et al. 2003). Other stimuli have 
been described to increase IL-8 expression by endothelial cells. Notably IL-33, a 
newly identified member of the IL-1 family, exerts this effect through interaction 
with the endothelial cell ST2 receptor which is itself induced by Th2 cytokines 
(Aoki et al. 2010;Yagami et al. 2010). 
 
Although outside the scope of the studies here, anaphylatoxins such as C5a 
may also influence endothelial cell function in inflammation by inducing 
leukocyte rolling/adhesion molecules such as P-selectin which are important in 
inflammatory cell recruitment (Bloemen et al. 2007). Again a variety of cytokines, 
including TNF-α, IFN-γ, IL-4 and IL-13 also increase the endothelial expression 
of adhesion molecules and may be responsible for the delayed leukocyte 
recruitment that characterises the “late phase” of acute allergic reactions (Pober 
et al. 1986;Bochner et al. 1995). Nevertheless, in spite of extensive data about 
the existence of endothelial cell/leukocyte adhesion molecule pairs, the extent to 
which their expression has an impact on the course of asthma awaits 





Other possible effects of anaphylatoxins on endothelial cells outside the scope 
of the present experiments include the possibility that they may regulate eNOS 
production and thus local vascular tone (Gifford et al. 2004) and matrix 
metalloproteinases (Mauro, Buscemi, & Gerbino 2010). In addition, preliminary 
experiments suggest that endothelial cells may release key asthma-relevant 
cytokines such as GM-CSF (Burg et al. 2002).    
 
The data show that endothelial cells of diverse origin express receptors for the 
anaphylatoxins C3a and C5a and that these may influence cellular proliferation 
and regulate the production of a number cytokines and growth factors relevant 
to inflammation and tissue remodelling in asthma and other diseases. It is 
particularly intriguing that complement may under certain conditions be able to 





















Chapter 8:  Summary & 
Conclusion
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8.1 Summary & Conclusion 
At the outset of this work, in order to further investigate the possible role of 
complement and its receptors in asthma pathogenesis it was hypothesised that: 
 There is elevated expression and or deposition of the complement 
fragments C3, C3d and C5b-9 in the bronchial mucosa of asthmatics 
compared to controls;  
 There is elevated expression/deposition of the complement fragments 
C3, C3d and C5b-9 in the bronchial mucosa of atopic asthmatics 
following bronchial allergen challenge;  
 C3a and C5a play a role in effecting airway remodelling by acting on 
structural cells, including epithelial cells, endothelial cells, fibroblasts 
and smooth muscle cells to induce remodelling changes or production of 
remodelling mediators.  
 
To address these hypotheses, experiments described in chapter 3 assessed the 
deposition/expression of some complement fragments, both anaphylatoxin 
receptors in the bronchial mucosa of asthmatics compared to controls, and in 
addition in a group of mild, atopic asthmatics before and after allergen bronchial 
challenge. I also measured the numbers of FGF2 immunoreactive cells in the 
epithelium and submucosa of the asthmatics “at baseline” compared to controls. 
Experiments described in chapters 4-7 assessed effects of anaphylatoxins on 
key structural cells involved in airways remodelling in asthma. 
 
The histological data somewhat supported the first hypothesis: the most striking 
finding was the expression of C3a and C5a receptors by at least a 
subpopulation of a wide variety of structural cell types within the bronchial 
mucosa, consistent with at least the propensity of these cells to respond to 
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complement fragments. This was confirmed by subsequent in vitro experiments, 
which clearly showed that lung epithelial, fibroblast, smooth muscle and 
endothelial cells express anaphylatoxin receptors. With regard to expression of 
complement fragments themselves, the picture was less clear and hampered by 
the lack of availability of a full range of suitable reagents. This necessitated 
study of the expression of C3, C3d and C5b-9 as surrogates of C3a and C5a 
production and while there is some justification for this, as expanded in chapter 
3, it is not a direct measurement of local C3a and C5a expression, which may be 
particularly pertinent to dynamic situations such as following allergen challenge 
where changes in local expression of complement components could in theory 
vary quite substantially with time. Nevertheless the data do provide some 
circumstantial evidence for involvement of some of the components of the 
complement cascade in asthma in the sense that elevated C3 and C5b-9 
immunoreactivity was observed in the epithelial, smooth muscle and 
submucosal regions of sections of bronchial biopsies from asthmatics compared 
to controls. Expression of C3d and C3aR immunoreactivity were likewise 
elevated although only in epithelium and smooth muscle respectively. On the 
other hand, correlation with disease severity was poor and might have been 
influenced by variable anti-asthma therapy, since the effects, if any, of anti-
asthma medications on the production and expression of complement 
components within the bronchial mucosa are unknown. Furthermore, it is 
impossible to determine from histological studies whether production of 
complement fragments reflects local synthesis, in which case overall production 
might be expected to reflect the numbers of cells involved in the production, or 
binding of components delivered through the circulation. Finally, since the 
possible functional effects of complement components in the asthmatic bronchial 
mucosa are unknown it is difficult to envisage, at our present stage of 
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knowledge, physiologically relevant functional “readouts” of complement activity 
other than the rather dubious one of static disease severity. 
 
With regard to correlation of disease severity with expression of complement 
components, the second hypothesis above was formulated to explore the effects 
of acute exacerbation of asthma by allergen challenge on local expression of 
complement components. As with the static experiments, changes in expression 
of the measurable complement components were not at all impressive following 
challenge; again it was possible to explore these changes at only one single 
time point (24 hours) following challenge and it could be argued that, in terms of 
possible early complement activation following challenge and the peak influx of 
inflammatory cells, this time point may have been too late. 
 
With regard to the third and final hypothesis, the testing of which is reported in 
chapters 4-7, experiments with cultured cells were variable in substantiating the 
hypothesis. This is partly because, owing to the great difficulty in outgrowing 
primary structural cell lines from biopsies, in many cases the total numbers of 
experiments which could be performed within a reasonable time (and expense) 
frame was limited and interpretation therefore hampered by lack of statistical 
power. This is particularly true of the experiments addressing the effects of C3a 
and C5a on structural cellular proliferation, and exacerbated by the relatively low 
sensitivity and higher inherent variability of the colorimetric proliferation assay. 
Thus while C3a clearly increased fibroblast and endothelial cell proliferation at a 
range of physiological concentrations, its effects were less clear on smooth 
muscle and epithelial cell proliferation, probably owing to lack of statistical 
power. In contrast the effects of C5a on proliferation of all four of the structural 
cell types were equivocal, although by the same argument this could also reflect 
statistical under powering. 
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Apart from proliferation of airways structural cells, which is considered a key 
feature of the “remodelling” process, another focal point for investigation of the 
effects of C3a and C5a on remodelling emerged as their effects on the 
production of remodelling growth factors, and in particular FGF2 by the airways 
structural cells. As has been emphasised previously in the relevant chapters, 
FGF2 is one of the key remodelling growth factors implicated in mucosal 
remodelling and therefore arguably an important “readout” for the effects of 
complement complements on remodelling processes. Furthermore, all of the 
airways structural cell types studied in this thesis were capable of spontaneous 
FGF2 release in culture at the protein level. Fascinatingly, many, but not all of 
the observed effects of C3a and C5a on FGF2 production were inhibitory. Again, 
interpretation was somewhat impaired by the small numbers of experiments 
reducing statistical powering. Thus C3a clearly inhibited the release of FGF2 
protein by bronchial epithelial cells; this was less clear in the case of C5a 
because of the limited numbers of possible experiments. While C3a appeared to 
increase FGF2 production by lung fibroblasts, C5a appeared to do the reverse 
although the poor quality of the concentration-response relationship in this 
particular experiment suggests a need for caution and the necessity for further 
verification.  Both C3a and C5a inhibited FGF2 production by airways smooth 
muscle cells and endothelial cells, although again the poor 
concentration/response relationship observed with C5a in the case of 
endothelial cells suggests a need for caution pending further experiments. 
 
Another area which will require future further clarification is the relationship 
between FGF2 mRNA and protein synthesis: while in many of the experiments 
the anaphylatoxins were observed to reduce FGF2 mRNA and protein 
expression in concert, this was not always the case: for example, in chapter 7 
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(endothelial cells) C3a appeared to increase production of FGF2 mRNA at the 
time points measured, whereas release of FGF2 protein in culture was reduced. 
These discrepancies will be fully clarified only when the full time course of 
alteration of FGF2 mRNA expression by complement components in the various 
target cells is fully understood (using sufficient numbers of experiments to 
ensure statistical power), as well as the dynamics of how changes in mRNA 
synthesis affect protein synthesis and whether all synthesised protein is 
secreted into culture supernatants. The pathophysiological consequences of 
these phenomena remain to be explored but clearly the data show that 
complement components may both promote and inhibit local production of key 
remodelling mediators, providing support for hypothesis three above. 
 
In addition, the data suggest that C3a at a high physiological concentration can 
increase IL-6 production by fibroblasts while C5a can increase IL-8 production 
by endothelial cells. Thus the effects of anaphylatoxins may not be limited to 
regulation of growth factor expression, although again the pathophysiological 
consequences, if any, of these observations remain to be explored. 
 
The main significance of this work is that it has shed light on the nature of 
expression of complement fragments, anaphylatoxin receptors and the growth 
factor FGF2 in the bronchial mucosa using an in vivo approach. The in vitro data 
have extended the functional implications of these observations to show that 
anaphylatoxins may influence a variety of key remodelling mechanisms in the 
asthmatic bronchial mucosa. The effects of the anaphylatoxins on the structural 
cells synthesising the various mediators that were explored in the chapters of 
this thesis are summarised in Figure 8.1. 


























C3a: ↑FGF2, C5a: -FGF2 (g) 




C5a: ↓FGF2 ↑ FGF11 ↑ FGFR1; C3a: ↑FGF2(p)
 
Figure 8.1 Potential effects of anaphylatoxins on structural cells of the airways as revealed by the work in this thesis. 
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8.2 Future Directions 
The results of the present study motivate research in several different avenues. 
Given that they express appropriate receptors for, and are capable of 
physiological responses to the anaphylatoxins, the effects of anaphylatoxins on 
the four structural cell types looked at in this thesis surely merits further, in depth 
exploration under the umbrella of “remodelling”. 
 
It will be appreciated from the work presented in this thesis that there are few 
established and readily available techniques of measuring complement 
components, and this deserves development (for example detection in induced 
sputum, bronchial brushings etc. as well as histologically in tissues). 
 
One direction for the future would be to expand and amplify the experiments 
presented in this thesis to clarify some of the equivocal effects suggested by 
some of the data, and to allow a more global analysis of the effects of 
anaphylatoxins on purified populations of target structural cells using, for 
example, microarray analysis. This was attempted in a preliminary form when 
screening for effects of the anaphylatoxins on FGF production by airways 
structural cells in this thesis but could be expanded.  Excessive mucus 
production by epithelial cells is another feature of remodelling and so it would be 
worthwhile exploring the effects of the anaphylatoxins on the expression of 
mucin genes. Studies on smooth muscle cells and fibroblasts could further be 
expanded by exploring possible effects of anaphylatoxins on myofibroblast 
differentiation (marked by the induction of smooth muscle actin) and their 
synthesis of interstitial proteins such as collagen and fibronectin. Since 
angiogenesis is also an important feature of airways remodelling; direct effects 
of the anaphylatoxins on angiogenesis in vitro could be sought, and any effects 
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clarified by investigation of effects on the production by endothelial cells of 
relevant mediators such as VEGF and its receptors. 
 
In addition to looking at expression of complement components in the bronchial 
mucosa, it would also be of interest (and a challenge) to search for evidence 
that structural cells in asthma can actually manufacture any of the complement 
components C1-C9. This could be done in various ways, for example by 
comparing the gene expression profiles of asthmatics and normal control 
airways structural cells outgrown ex vivo as mentioned, although this would be a 
greater challenge than usual because the production of complement 
components such as anaphylatoxins can be triggered by a variety of pathways 
and production depends on the activities not of single enzymes but on cascades 
of enzymes. 
 
To further build on the research presented here, it would be useful to extend the 
methods used for example to more sophisticated cell culture systems (for 
example recreating the air interface of bronchial epithelial cells or co-culturing 
epithelial cells and fibroblasts), as well as further exploiting the use of animal 
models, either with relevant gene deletions or by using complement antagonists 
(for example the data in this thesis suggest that it would be interesting to 
observe the effects of C3a gene deletion/pharmacological blockade on chronic 
remodelling changes in the airways, of which there are now several animal 
“models”). 
 
Above all it would be highly desirable to understand the possible role of 
complement components in asthma to the extent that biomarkers of their 
activity, either systemic or mucosal, can be used to correlate their activity with 
airways remodelling in asthma in the longer term. 
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The pathogenesis of asthma and associated airways remodelling remains a 
challenging subject with much more work still to be done.  The work presented 
in this thesis has only begun to scratch the surface of investigation of the 
possible role of complement components; nevertheless it has made a significant 
contribution to new knowledge, principally by highlighting the possibility that 
complement components can be added to the list of many local influences which 
may drive remodelling changes, either directly or indirectly, in the asthmatic 
bronchial mucosa.  It has been demonstrated that a surprisingly wide range of 
structural cells in the bronchial mucosa express anaphylatoxin receptors and 
posses at least the propensity to synthesise complement components. In a 
variety of airways structural cells, the anaphylatoxins exert measurable effects 
on the production of a range of remodelling and pro-inflammatory mediators, as 
well as cellular proliferation, suggesting a significant and long term role in 
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